CN110408600A - A hybridoma cell line secreting anti-heavy metal copper ion monoclonal antibody and its application - Google Patents
A hybridoma cell line secreting anti-heavy metal copper ion monoclonal antibody and its application Download PDFInfo
- Publication number
- CN110408600A CN110408600A CN201811506878.7A CN201811506878A CN110408600A CN 110408600 A CN110408600 A CN 110408600A CN 201811506878 A CN201811506878 A CN 201811506878A CN 110408600 A CN110408600 A CN 110408600A
- Authority
- CN
- China
- Prior art keywords
- solution
- heavy metal
- copper ion
- add
- monoclonal antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910001385 heavy metal Inorganic materials 0.000 title claims abstract description 84
- 229910001431 copper ion Inorganic materials 0.000 title claims abstract description 78
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 title claims abstract description 74
- 210000004408 hybridoma Anatomy 0.000 title claims abstract description 28
- 230000003248 secreting effect Effects 0.000 title claims abstract description 6
- 238000002360 preparation method Methods 0.000 claims abstract description 21
- 239000010949 copper Substances 0.000 claims abstract description 17
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229910052802 copper Inorganic materials 0.000 claims abstract description 16
- 239000000243 solution Substances 0.000 claims description 276
- 239000000427 antigen Substances 0.000 claims description 78
- 102000036639 antigens Human genes 0.000 claims description 78
- 108091007433 antigens Proteins 0.000 claims description 78
- 238000006243 chemical reaction Methods 0.000 claims description 51
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 39
- 239000007995 HEPES buffer Substances 0.000 claims description 30
- 210000004027 cell Anatomy 0.000 claims description 30
- 239000002738 chelating agent Substances 0.000 claims description 29
- 230000003053 immunization Effects 0.000 claims description 29
- 238000002649 immunization Methods 0.000 claims description 29
- 230000015572 biosynthetic process Effects 0.000 claims description 23
- 238000003786 synthesis reaction Methods 0.000 claims description 23
- 241000699670 Mus sp. Species 0.000 claims description 21
- XTVVROIMIGLXTD-UHFFFAOYSA-N copper(II) nitrate Chemical compound [Cu+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O XTVVROIMIGLXTD-UHFFFAOYSA-N 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 20
- 229910021642 ultra pure water Inorganic materials 0.000 claims description 19
- 239000012498 ultrapure water Substances 0.000 claims description 19
- 238000002965 ELISA Methods 0.000 claims description 18
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 16
- 239000012279 sodium borohydride Substances 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 15
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 12
- 229940098773 bovine serum albumin Drugs 0.000 claims description 12
- 238000003760 magnetic stirring Methods 0.000 claims description 12
- 206010003445 Ascites Diseases 0.000 claims description 11
- 238000000502 dialysis Methods 0.000 claims description 11
- 101000609762 Gallus gallus Ovalbumin Proteins 0.000 claims description 10
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 10
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 10
- 238000000108 ultra-filtration Methods 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 9
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 claims description 8
- 230000007910 cell fusion Effects 0.000 claims description 7
- 238000012216 screening Methods 0.000 claims description 7
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 claims description 6
- 238000000746 purification Methods 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 210000001015 abdomen Anatomy 0.000 claims description 3
- 210000001099 axilla Anatomy 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 3
- 238000003113 dilution method Methods 0.000 claims description 3
- 244000005700 microbiome Species 0.000 claims description 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 3
- 210000004989 spleen cell Anatomy 0.000 claims description 3
- 210000000683 abdominal cavity Anatomy 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 238000003018 immunoassay Methods 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- DBLXOVFQHHSKRC-UHFFFAOYSA-N ethanesulfonic acid;2-piperazin-1-ylethanol Chemical compound CCS(O)(=O)=O.OCCN1CCNCC1 DBLXOVFQHHSKRC-UHFFFAOYSA-N 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 238000004321 preservation Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 abstract description 23
- 230000035945 sensitivity Effects 0.000 abstract description 7
- 230000007613 environmental effect Effects 0.000 abstract description 3
- 102000004169 proteins and genes Human genes 0.000 description 48
- 108090000623 proteins and genes Proteins 0.000 description 48
- 230000008878 coupling Effects 0.000 description 27
- 238000010168 coupling process Methods 0.000 description 27
- 238000005859 coupling reaction Methods 0.000 description 27
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 25
- 239000011248 coating agent Substances 0.000 description 23
- 238000000576 coating method Methods 0.000 description 23
- 150000002500 ions Chemical class 0.000 description 23
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 20
- 238000001228 spectrum Methods 0.000 description 16
- 238000002835 absorbance Methods 0.000 description 15
- 230000000903 blocking effect Effects 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 230000001588 bifunctional effect Effects 0.000 description 13
- 125000000623 heterocyclic group Chemical group 0.000 description 12
- 238000005406 washing Methods 0.000 description 11
- 239000000872 buffer Substances 0.000 description 10
- 238000009010 Bradford assay Methods 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 9
- 230000001808 coupling effect Effects 0.000 description 9
- 238000001095 inductively coupled plasma mass spectrometry Methods 0.000 description 9
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 8
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- 238000001962 electrophoresis Methods 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 241000283707 Capra Species 0.000 description 5
- 230000002860 competitive effect Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 239000008399 tap water Substances 0.000 description 5
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 235000020679 tap water Nutrition 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 239000007640 basal medium Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002354 inductively-coupled plasma atomic emission spectroscopy Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028400 Mutagenic effect Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- MUUGCDGGIVCSDT-UHFFFAOYSA-N [NH4+].[NH4+].[O-]S([O-])(=O)=O.CCCCCCCC(O)=O Chemical compound [NH4+].[NH4+].[O-]S([O-])(=O)=O.CCCCCCCC(O)=O MUUGCDGGIVCSDT-UHFFFAOYSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000570 acute poisoning Toxicity 0.000 description 1
- 238000003968 anodic stripping voltammetry Methods 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 238000001479 atomic absorption spectroscopy Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 231100000739 chronic poisoning Toxicity 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000004993 emission spectroscopy Methods 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000009616 inductively coupled plasma Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 231100000243 mutagenic effect Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 231100000378 teratogenic Toxicity 0.000 description 1
- 230000003390 teratogenic effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
技术领域technical field
本发明属于免疫化学检测技术领域,具体涉及一株分泌抗重金属铜离子单克隆抗体的杂交瘤细胞株及其应用。The invention belongs to the technical field of immunochemical detection, in particular to a hybridoma cell strain secreting anti-heavy metal copper ion monoclonal antibodies and its application.
背景技术Background technique
重金属污染主要指铜、镉、汞、镍、铬、砷、锌、铜等污染物对环境的污染。重金属分布广泛、难以降解,可通过大气、水、食物链进入人体,与体内蛋白质及各种酶发生作用,使它们失去活性,并在某些器官中富集,如果超过人体所能耐受的限度,会造成人体急性或慢性中毒,具有致癌、致畸及致突变作用,对人体具有很大的危害。因此,加强重金属在环境、农产品和食品中残留检测成为保障重金属安全的重要手段,而新形势下检测新技术的研究和开发显得尤为迫切。Heavy metal pollution mainly refers to the environmental pollution caused by pollutants such as copper, cadmium, mercury, nickel, chromium, arsenic, zinc, and copper. Heavy metals are widely distributed and difficult to degrade. They can enter the human body through the atmosphere, water and food chain, and interact with proteins and various enzymes in the body, making them inactive and enriched in some organs. , it will cause acute or chronic poisoning of human body, and has carcinogenic, teratogenic and mutagenic effects, and has great harm to human body. Therefore, strengthening the detection of heavy metal residues in the environment, agricultural products and food has become an important means to ensure the safety of heavy metals, and the research and development of new detection technologies under the new situation is particularly urgent.
传统的重金属检测方法主要采用原子吸收光谱分析(Atomic AbsorptionSpectroscopy,AAS)、电感耦合等离子发射光谱(InductiveLy CoupLedpLasma AtomicEmission Spectroscopy,ICP-AES)、阳极溶出伏安法(Anodic Stripping VoLtammetry,ASV)、色谱法和各种联用检测方法。这些方法虽然能对各种环境样品中的重金属离子进行有效分析,但大多需要大型仪器,分析方法成本高,样品需要经过消解,分析时间长,不适于重金属的现场快速检测,难以适应环境及市场产品的现场抽查、生产企业自查及产品进出口快速通关的要求。Traditional heavy metal detection methods mainly use Atomic Absorption Spectroscopy (AAS), Inductively Coupled Plasma Emission Spectroscopy (InductiveLy CoupLedpLasma AtomicEmission Spectroscopy, ICP-AES), Anodic Stripping Voltammetry (ASV), chromatography and Various combined detection methods. Although these methods can effectively analyze heavy metal ions in various environmental samples, most of them require large-scale instruments, the cost of analysis methods is high, the samples need to be digested, the analysis time is long, and they are not suitable for on-site rapid detection of heavy metals, and are difficult to adapt to the environment and market. Requirements for spot inspection of products, self-inspection of production enterprises and rapid customs clearance for product import and export.
免疫学检测技术具有检测速度快、分析容量大、费用低廉、仪器简单易携、使用人员技术要求不高,容易普及和推广、灵敏度高和选择性强等优点,尤其适合现场筛选和大量样品的快速分析,已成为21世纪最具竞争性和挑战性的检测分析技术。Immunological detection technology has the advantages of fast detection speed, large analysis capacity, low cost, simple and portable instrument, low technical requirements for users, easy popularization and promotion, high sensitivity and strong selectivity, etc. It is especially suitable for on-site screening and analysis of a large number of samples. Rapid analysis has become the most competitive and challenging detection and analysis technology in the 21st century.
重金属离子免疫学检测的关键在于抗重金属特异性抗体的制备,而特异性抗体制备的关键又在于优质重金属免疫原的合成,因此,如何制备优质重金属人工抗原,如何制备抗重金属特异性抗体,建立更快速、更经济的免疫分析法检测重金属离子成为需要解决的问题。The key to the immunological detection of heavy metal ions is the preparation of anti-heavy metal specific antibodies, and the key to the preparation of specific antibodies lies in the synthesis of high-quality heavy metal immunogens. Therefore, how to prepare high-quality artificial antigens for heavy metals, how to prepare anti-heavy metal specific antibodies, and establish Faster and more economical immunoassays for the detection of heavy metal ions have become a problem to be solved.
发明内容SUMMARY OF THE INVENTION
为克服现有技术的缺陷,本发明提供一株分泌抗重金属铜离子单克隆抗体的杂交瘤细胞株及其应用。In order to overcome the defects of the prior art, the present invention provides a hybridoma cell line secreting anti-heavy metal copper ion monoclonal antibody and its application.
一株分泌抗重金属铜离子单克隆抗体的杂交瘤细胞株,已经保藏于中国微生物菌种保藏管理委员会普通微生物中心,保藏编号为CGMCC No.16388。A hybridoma cell line that secretes monoclonal antibodies against heavy metal copper ions has been deposited in the General Microbiology Center of the China Microorganism Culture Collection and Management Committee, and the deposit number is CGMCC No.16388.
抗重金属铜离子单克隆抗体,它由保藏编号为CGMCC No.16388的杂交瘤细胞株分泌产生。The anti-heavy metal copper ion monoclonal antibody is secreted and produced by the hybridoma cell line whose deposit number is CGMCC No.16388.
杂交瘤细胞株CGMCC No.16388或者其分泌的单克隆抗体在铜离子免疫检测中的应用。Application of hybridoma cell line CGMCC No.16388 or its secreted monoclonal antibody in copper ion immunodetection.
本发明采用以下技术方案:The present invention adopts following technical scheme:
一种分泌抗重金属铜离子单克隆抗体的杂交瘤细胞株的制备方法,该方法用于制备以上所述的杂交瘤细胞株,包括以下步骤:A preparation method of a hybridoma cell line secreting anti-heavy metal copper ion monoclonal antibody, the method is used for preparing the above-mentioned hybridoma cell line, comprising the following steps:
(1)杂环类双功能螯合剂铜离子人工抗原的合成及鉴定:(1) Synthesis and identification of heterocyclic bifunctional chelating agent copper ion artificial antigen:
称取5~8mg 2-S-(3-氨基苯)-1,4,7三氮杂环壬烷-1,4,7-三乙酸(简写为o-NH2-Bn-NOTA),溶解于2mL 0.01mol·L-1、pH7.4 4-羟乙基哌嗪乙磺酸HEPES溶液,制得螯合剂溶液,此溶液为A液;Weigh 5-8 mg of 2-S-(3-aminobenzene)-1,4,7 triazacyclononane-1,4,7-triacetic acid (abbreviated as o-NH 2 -Bn-NOTA), dissolve In 2mL of 0.01mol·L -1 , pH7.4 4-hydroxyethylpiperazineethanesulfonic acid HEPES solution, a chelating agent solution was prepared, and this solution was A solution;
称取70.33mg硝酸铜溶解于5mL超纯水中,制得浓度为7.5×10-2mol·L-1的硝酸铜溶液,此溶液为B液;Weigh 70.33 mg of copper nitrate and dissolve it in 5 mL of ultrapure water to prepare a copper nitrate solution with a concentration of 7.5×10 -2 mol·L -1 , which is solution B;
将150~200μL的B液加入到A液中,室温下避光反应3~5h,此反应液为C液;Add 150-200 μL of solution B to solution A, and react in the dark for 3-5 hours at room temperature, this reaction solution is solution C;
向C液中逐滴加入500~800μL,20mmol·L-1的戊二醛溶液,室温避光反应过夜,此反应液为D液;Add 500-800 μL, 20 mmol·L -1 glutaraldehyde solution dropwise to solution C, react overnight at room temperature in the dark, and this reaction solution is solution D;
称取20~30mg牛血清白蛋白BSA或鸡卵清蛋白OVA溶解于3mL HEPES,室温下磁力搅拌混匀,此反应液为E液;Weigh 20-30 mg of bovine serum albumin BSA or chicken ovalbumin OVA, dissolve it in 3 mL of HEPES, and mix with magnetic stirring at room temperature. This reaction solution is E solution;
将D液逐滴加入到E液中,室温下避光反应24h,后逐滴加入150~200μL硼氢化钠溶液(20mg溶解于200μL超纯水中),室温下避光反应1h;Add solution D to solution E dropwise, react in the dark for 24 hours at room temperature, then add 150-200 μL sodium borohydride solution (20 mg dissolved in 200 μL ultrapure water) dropwise, and react in the dark for 1 hour at room temperature;
反应液先用8KD的透析袋透析3~5次,再用30KD的超滤离心管7000~9000r·min-1离心洗涤3~5次,每次15~20min,用5~10mL的0.01M,pH7.4的HEPES溶液复溶,后分装,-20℃低温保存,制得重金属铜人工抗原Cu-L2-BSA或者Cu-L2-OVA,L2表示2-S-(3-氨基苯)-1,4,7三氮杂环壬烷-1,4,7-三乙酸The reaction solution was first dialyzed with an 8KD dialysis bag for 3 to 5 times, and then centrifuged with a 30KD ultrafiltration centrifuge tube at 7000 to 9000 r·min -1 for 3 to 5 times, for 15 to 20 minutes each time, with 5 to 10 mL of 0.01M, The HEPES solution with pH 7.4 was reconstituted, then packaged and stored at -20°C to prepare the heavy metal copper artificial antigen Cu-L 2 -BSA or Cu-L 2 -OVA, where L 2 represents 2-S-(3-amino Benzene)-1,4,7triazacyclononane-1,4,7-triacetic acid
合成路线为:The synthetic route is:
采取紫外扫描和SDS-PAGE鉴定其偶联效果,采用ICP-MS法和Bradford法分别测定重金属离子和蛋白浓度,计算人工抗原的偶联结合比。The coupling effect was identified by UV scanning and SDS-PAGE. The concentrations of heavy metal ions and proteins were determined by ICP-MS and Bradford methods, respectively, and the coupling-binding ratio of artificial antigens was calculated.
(2)小鼠的免疫:(2) Immunization of mice:
选择健康的6~8周龄的雌性BALB/C小鼠进行免疫。将制备的重金属铜人工抗原Cu-L2-BSA与等体积弗氏完全佐剂采用注射器加压充分混合乳化后,通过腹部和腋下多点注射。后每间隔21d(天)进行加强免疫,3次加强免疫后采血测定效价,效价采用间接ELISA方法测定。当效价不再明显升高时进行最后末免,末免3d后进行细胞融合。免疫过程中第一次免疫使用弗氏完全佐剂,加强免疫采用弗氏不完全佐剂,末免不使用佐剂,直接免疫原注射免疫。Healthy 6-8 week old female BALB/C mice were selected for immunization. The prepared heavy metal copper artificial antigen Cu-L 2 -BSA and an equal volume of Freund's complete adjuvant were fully mixed and emulsified by syringe pressure, and then injected through the abdomen and axilla at multiple points. Afterwards, booster immunization was performed every 21 days (days), and blood was collected to measure the titer after 3 booster immunizations, and the titer was determined by indirect ELISA method. When the titer was no longer significantly increased, the final immune was performed, and cell fusion was performed 3 days after the final immune. In the immunization process, Freund's complete adjuvant was used for the first immunization, and Freund's incomplete adjuvant was used for booster immunization.
(3)细胞融合与细胞株筛选:(3) Cell fusion and cell line screening:
通过聚乙二醇法将小鼠脾细胞与小鼠骨髓瘤细胞SP2/0按照5~10:1的比例进行融合,HAT选择性培养基培养,间接ELISA检测阳性孔,并对阳性孔进一步利用间接竞争ELISA测定阳性细胞孔的抑制效果,随后对抑制效果好的阳性孔进行有限稀释法进行3~4次克隆,最后用间接竞争ELISA法验证后筛选获得杂交瘤细胞株6F9。The mouse spleen cells were fused with mouse myeloma cells SP2/0 in a ratio of 5 to 10:1 by the polyethylene glycol method, cultured in HAT selective medium, and the positive wells were detected by indirect ELISA, and the positive wells were further utilized. Indirect competition ELISA was used to measure the inhibitory effect of positive cell wells, and then the positive wells with good inhibitory effect were cloned 3-4 times by limiting dilution method. Finally, the hybridoma cell line 6F9 was obtained after verification by indirect competitive ELISA method.
抗重金属铜离子单克隆抗体的制备方法,包括以下步骤:The preparation method of anti-heavy metal copper ion monoclonal antibody comprises the following steps:
在BALB/C小鼠腹腔注射降植烷0.3ml/只,7~10d(天)后同法注射筛选到的6F9单克隆细胞株细胞,待小鼠腹腔明显胀大后无菌操作抽取腹水,离心除去油脂沉淀后,即得小鼠腹水McAb;BALB/C mice were intraperitoneally injected with 0.3ml/mice of pristane, and the screened 6F9 monoclonal cells were injected in the same way after 7-10 days (days). After centrifugation to remove the grease precipitation, the mouse ascites McAb was obtained;
腹水纯化后,得到纯化单克隆抗体。After purification of the ascites fluid, purified monoclonal antibodies were obtained.
进一步地,将杂环类双功能螯合剂L2分别替换成2-S-(2-氨基苯)-1,4,7三氮杂环壬烷-1,4,7-三乙酸(简写为o-NH2-Bn-NOTA)或者2-S-(4-氨基苯)-1,4,7三氮杂环壬烷-1,4,7-三乙酸(简写为p-NH2-Bn-NOTA)或者2-S-[4-(3-氨基丙基)-苯]-1,4,7三氮杂环壬烷-1,4,7-三乙酸,采用以上相同的制备方法可以制得不同的铜离子人工抗原、杂交瘤细胞株、抗重金属铜离子单克隆抗体。Further, the heterocyclic bifunctional chelating agent L 2 was respectively replaced with 2-S-(2-aminobenzene)-1,4,7 triazacyclononane-1,4,7-triacetic acid (abbreviated as o-NH 2 -Bn-NOTA) or 2-S-(4-aminobenzene)-1,4,7 triazacyclononane-1,4,7-triacetic acid (abbreviated as p-NH 2 -Bn -NOTA) or 2-S-[4-(3-aminopropyl)-benzene]-1,4,7 triazacyclononane-1,4,7-triacetic acid, the same preparation method above can be used Different copper ion artificial antigens, hybridoma cell lines and anti-heavy metal copper ion monoclonal antibodies were prepared.
进一步地,将牛血清白蛋白BSA替换为钥孔血蓝蛋白KLH或者其他载体蛋白,采用以上相同的制备方法,可以制备不同的铜离子人工抗原、杂交瘤细胞株、单克隆抗体。Further, by replacing bovine serum albumin BSA with keyhole limpet hemocyanin KLH or other carrier proteins, different copper ion artificial antigens, hybridoma cell lines and monoclonal antibodies can be prepared by using the same preparation method above.
本发明的有益效果是:The beneficial effects of the present invention are:
(1)本发明采用杂环类双功能螯合剂m-NH2-Bn-NOTA制备铜离子人工抗原,该螯合剂在结构上能更好的结合重金属离子,同时在空间结构上能更好地将重金属铜离子的结构展现出来,制备得到的铜离子人工抗原具有较强的特异性。(1) The present invention adopts the heterocyclic bifunctional chelating agent m-NH 2 -Bn-NOTA to prepare copper ion artificial antigen. The chelating agent can better bind heavy metal ions in structure and can better The structure of the heavy metal copper ion is revealed, and the prepared copper ion artificial antigen has strong specificity.
(2)本发明制备得到的杂交瘤细胞株6F9能够分泌重金属铜离子单克隆抗体,该单克隆抗体特异性较强,对铜离子螯合剂复合物具有较好地灵敏度,IC20值为0.14ng·mL-1,能够用于快速检测重金属铜离子。该抗铜离子单克隆抗体可以用于环境样品中铜离子的残留检测。(2) The hybridoma cell line 6F9 prepared by the present invention can secrete heavy metal copper ion monoclonal antibody, the monoclonal antibody has strong specificity and good sensitivity to copper ion chelator complexes, and the IC 20 value is 0.14ng ·mL -1 , which can be used for rapid detection of heavy metal copper ions. The anti-copper ion monoclonal antibody can be used for the residual detection of copper ion in environmental samples.
附图说明Description of drawings
图1为实施例1、2中铜离子人工抗原合成示意图(其中,Protein代表牛血清白蛋白BSA或者鸡卵清蛋白OVA)。Figure 1 is a schematic diagram of the synthesis of copper ion artificial antigens in Examples 1 and 2 (wherein Protein represents bovine serum albumin BSA or chicken ovalbumin OVA).
图2为实施例3、4中铜离子人工抗原合成示意图(其中,Protein代表牛血清白蛋白BSA或者鸡卵清蛋白OVA)。Figure 2 is a schematic diagram of the synthesis of artificial antigens of copper ions in Examples 3 and 4 (wherein Protein represents bovine serum albumin BSA or chicken ovalbumin OVA).
图3为实施例5、6中铜离子人工抗原合成示意图(其中,Protein代表牛血清白蛋白BSA或者鸡卵清蛋白OVA)。Figure 3 is a schematic diagram of the synthesis of artificial antigens of copper ions in Examples 5 and 6 (wherein Protein represents bovine serum albumin BSA or chicken ovalbumin OVA).
图4为实施例7、8中铜离子人工抗原合成示意图(其中,Protein代表牛血清白蛋白BSA或者鸡卵清蛋白OVA)。Figure 4 is a schematic diagram of the synthesis of artificial antigens of copper ions in Examples 7 and 8 (wherein, Protein represents bovine serum albumin BSA or chicken ovalbumin OVA).
具体实施方式Detailed ways
以下对本发明的技术方案做进一步详细说明,应当指出的是,具体实施方式只是对本发明的详细说明,不应视为对本发明的限定。The technical solutions of the present invention are further described in detail below. It should be noted that the specific embodiments are only detailed descriptions of the present invention and should not be regarded as limitations of the present invention.
本发明所用的杂环类双功能螯合剂用L表示,实施例中杂环类双功能螯合剂分别为:2-S-(2-氨基苯)-1,4,7三氮杂环壬烷-1,4,7-三乙酸(简写为o-NH2-Bn-NOTA)用L1表示,2-S-(3-氨基苯)-1,4,7三氮杂环壬烷-1,4,7-三乙酸(简写为m-NH2-Bn-NOTA)用L2表示,2-S-(4-氨基苯)-1,4,7三氮杂环壬烷-1,4,7-三乙酸(简写为p-NH2-Bn-NOTA)用L3表示,2-S-[4-(3-氨基丙基)-苯]-1,4,7三氮杂环壬烷-1,4,7-三乙酸(简写为p-CH2CH2CH2NH2-Bn-NOTA)用L4表示,这些螯合剂均由商业途径购买得到。The heterocyclic bifunctional chelating agent used in the present invention is represented by L. In the embodiment, the heterocyclic bifunctional chelating agent is respectively: 2-S-(2-aminobenzene)-1,4,7 triazacyclononane -1,4,7-Triacetic acid (abbreviated as o-NH 2 -Bn-NOTA) is represented by L 1 , 2-S-(3-aminobenzene)-1,4,7 triazacyclononane-1 , 4,7-triacetic acid (abbreviated as m- NH2 -Bn-NOTA) is represented by L2, 2 -S-(4-aminobenzene)-1,4,7triazacyclononane-1,4 , 7-triacetic acid (abbreviated as p- NH2 -Bn-NOTA) is represented by L3, 2 -S-[4-(3-aminopropyl)-benzene]-1,4,7 triazacyclononane Alkane-1,4,7-triacetic acid (abbreviated as p-CH 2 CH 2 CH 2 CH 2 NH 2 -Bn-NOTA) is represented by L 4 , and these chelating agents are commercially available.
1.杂环类双功能螯合剂铜离子人工抗原的制备和鉴定1. Preparation and Identification of Heterocyclic Bifunctional Chelating Agent Copper Ion Artificial Antigen
实施例1Example 1
(1)铜离子人工抗原的合成:(1) Synthesis of copper ion artificial antigen:
称取6mg L1,溶解于2mL 0.01mol·L-1、pH 7.4 4-羟乙基哌嗪乙磺酸HEPES溶液,制得L1螯合剂溶液,此溶液为A液;Weigh 6 mg L 1 , dissolve it in 2 mL of 0.01 mol·L -1 , pH 7.4 4-hydroxyethylpiperazineethanesulfonic acid HEPES solution to obtain L 1 chelating agent solution, which is solution A;
称取70.33mg硝酸铜溶解于5mL超纯水中,制得浓度为7.5×10-2mol·L-1的硝酸铜溶液,此溶液为B液;Weigh 70.33 mg of copper nitrate and dissolve it in 5 mL of ultrapure water to prepare a copper nitrate solution with a concentration of 7.5×10 -2 mol·L -1 , which is solution B;
将180μL的B液加入到A液中,室温下避光反应3~5h,此反应液为C液;Add 180 μL of solution B to solution A, and react in the dark for 3 to 5 hours at room temperature. This reaction solution is solution C;
向C液中逐滴加入700μL,20mmol·L-1的戊二醛水溶液,室温避光反应过夜,此反应液为D液;Add 700 μL, 20 mmol·L -1 of glutaraldehyde aqueous solution dropwise to solution C, react overnight at room temperature in the dark, and this reaction solution is solution D;
称取20mg牛血清白蛋白BSA溶解于3mL HEPES,室温下磁力搅拌混匀,此反应液为E液;Weigh 20 mg of bovine serum albumin BSA, dissolve it in 3 mL of HEPES, and mix with magnetic stirring at room temperature. This reaction solution is E solution;
将D液逐滴加入到E液中,室温下避光反应24h,后逐滴加入150~200μL硼氢化钠溶液(20mg硼氢化钠溶解于200μL超纯水中),室温下避光反应1h;Add solution D to solution E dropwise, react in the dark for 24 hours at room temperature, then add 150-200 μL sodium borohydride solution dropwise (20 mg sodium borohydride dissolved in 200 μL ultrapure water), and react in the dark for 1 hour at room temperature;
反应液先用8KD的透析袋透析3~5次,再用30KD的超滤离心管7000~9000r·min-1离心洗涤3~5次,每次15~20min,用5~10mL的0.01mol·L-1,pH 7.4的HEPES溶液复溶,后分装,-20℃低温保存,制得重金属铜人工抗原Cu-L1-BSA,L1表示2-S-(2-氨基苯)-1,4,7三氮杂环壬烷-1,4,7-三乙酸(简写为o-NH2-Bn-NOTA)。The reaction solution was first dialyzed with an 8KD dialysis bag for 3 to 5 times, and then centrifuged with a 30KD ultrafiltration centrifuge tube at 7000 to 9000 r·min -1 for 3 to 5 times, 15 to 20 minutes each time, with 5 to 10 mL of 0.01 mol· L -1 , reconstituted in HEPES solution with pH 7.4, then packaged and stored at -20 ℃ to prepare heavy metal copper artificial antigen Cu-L 1 -BSA, L 1 represents 2-S-(2-aminobenzene)-1 , 4,7 triazacyclononane-1,4,7-triacetic acid (abbreviated as o- NH2 -Bn-NOTA).
(2)铜离子人工抗原的鉴定:(2) Identification of copper ion artificial antigens:
采取紫外扫描和SDS-PAGE鉴定其偶联效果,采用ICP-MS法和Bradford法分别测定重金属离子和蛋白浓度,计算人工抗原的偶联结合比。The coupling effect was identified by UV scanning and SDS-PAGE. The concentrations of heavy metal ions and proteins were determined by ICP-MS and Bradford methods, respectively, and the coupling-binding ratio of artificial antigens was calculated.
紫外扫描方案:BSA、Cu-L1-BSA和Cu-L1配制成浓度为1~5mg·mL-1范围内的溶液,测定200~400nm波长范围内的吸光度,并建立紫外扫描图谱,通过比较每种溶液的吸收曲线来鉴别合成是否成功。Ultraviolet scanning scheme: BSA, Cu-L 1 -BSA and Cu-L 1 were prepared into solutions with a concentration in the range of 1-5 mg·mL -1 , the absorbance in the wavelength range of 200-400 nm was measured, and an ultraviolet scanning spectrum was established. Comparing the absorbance curves of each solution to identify whether the synthesis was successful or not.
紫外扫描图谱中,Cu-L1-BSA溶液与BSA溶液相比,Cu-L1-BSA溶液的最大吸收波长有变化,说明偶联成功。In the UV scanning spectrum, compared with the BSA solution, the maximum absorption wavelength of the Cu -L 1 -BSA solution changed, indicating that the coupling was successful.
SDS-PAGE电泳方案:选择体积分数为5%浓缩胶,选择体积分数为10%分离胶,上样量10μL每孔,浓缩胶电压75V,分离胶电压100V,考马斯亮蓝染色1h,脱色4次,凝胶成像仪拍照分析。SDS-PAGE electrophoresis scheme: choose 5% stacking gel, choose 10% separating gel, load 10 μL per well, stacking gel voltage 75V, separating gel voltage 100V, Coomassie brilliant blue staining for 1h, destaining 4 times , and the gel imager photographed and analyzed.
经SDS-PAGE显示偶联物电泳条带比单一的蛋白条带有滞后现象,偶联物的分子量比单一蛋白分子量要大,说明偶联成功。SDS-PAGE showed that the electrophoretic band of the conjugate had a hysteresis phenomenon compared with that of the single protein, and the molecular weight of the conjugate was larger than that of the single protein, indicating that the coupling was successful.
通过测定重金属含量和偶联物蛋白浓度计算结合比为24:1。结合比为24:1,则表示一个蛋白分子上结合24个重金属离子。The binding ratio was calculated to be 24:1 by measuring heavy metal content and conjugate protein concentration. The binding ratio is 24:1, which means that 24 heavy metal ions are bound to one protein molecule.
实施例2Example 2
(1)铜离子人工抗原的合成:(1) Synthesis of copper ion artificial antigen:
称取7mg L1,溶解于2mL0.01mol·L-1、pH 7.4 4-羟乙基哌嗪乙磺酸HEPES溶液,制得L1螯合剂溶液,此溶液为A液;Weigh 7 mg L 1 , dissolve it in 2 mL of 0.01 mol·L -1 , pH 7.4 4-hydroxyethylpiperazineethanesulfonic acid HEPES solution to obtain L 1 chelating agent solution, which is solution A;
称取70.33mg硝酸铜溶解于5mL超纯水中,制得浓度为7.5×10-2mol·L-1的硝酸铜溶液,此溶液为B液;Weigh 70.33 mg of copper nitrate and dissolve it in 5 mL of ultrapure water to prepare a copper nitrate solution with a concentration of 7.5×10 -2 mol·L -1 , which is solution B;
将195μL的B液加入到A液中,室温下避光反应3~5h,此反应液为C液;Add 195 μL of solution B to solution A, and react in the dark for 3 to 5 hours at room temperature. This reaction solution is solution C;
向C液中逐滴加入720μL,20mmol·L-1的戊二醛溶液,室温避光反应过夜,此反应液为D液;Add 720 μL, 20 mmol·L -1 of glutaraldehyde solution dropwise to solution C, and react overnight in the dark at room temperature. This reaction solution is solution D;
称取20mg鸡卵清蛋白OVA溶解于3mL HEPES,室温下磁力搅拌混匀,此反应液为E液;Weigh 20 mg of chicken ovalbumin OVA and dissolve it in 3 mL of HEPES, and mix with magnetic stirring at room temperature. This reaction solution is E solution;
将D液逐滴加入到E液中,室温下避光反应24h,后逐滴加入150~200μL硼氢化钠溶液(20mg硼氢化钠溶解于200μL超纯水中),室温下避光反应1h;Add solution D to solution E dropwise, react in the dark for 24 hours at room temperature, then add 150-200 μL sodium borohydride solution dropwise (20 mg sodium borohydride dissolved in 200 μL ultrapure water), and react in the dark for 1 hour at room temperature;
反应液先用8KD的透析袋透析3~5次,再用30KD的超滤离心管7000~9000r·min-1离心洗涤3~5次,每次15~20min,用5~10mL的0.01mol·L-1,pH 7.4的HEPES溶液复溶,后分装,-20℃低温保存,制得重金属铜人工抗原Cu-L1-OVA,L1表示2-S-(2-氨基苯)-1,4,7三氮杂环壬烷-1,4,7-三乙酸(简写为o-NH2-Bn-NOTA)。The reaction solution was first dialyzed with an 8KD dialysis bag for 3 to 5 times, and then centrifuged with a 30KD ultrafiltration centrifuge tube at 7000 to 9000 r·min -1 for 3 to 5 times, 15 to 20 minutes each time, with 5 to 10 mL of 0.01 mol· L -1 , reconstituted in HEPES solution with pH 7.4, then packaged and stored at -20 ℃ to prepare heavy metal copper artificial antigen Cu-L 1 -OVA, L 1 represents 2-S-(2-aminobenzene)-1 , 4,7 triazacyclononane-1,4,7-triacetic acid (abbreviated as o- NH2 -Bn-NOTA).
(2)人工抗原的鉴定:(2) Identification of artificial antigens:
采取紫外扫描和SDS-PAGE鉴定其偶联效果,采用ICP-MS法和Bradford法分别测定重金属离子和蛋白浓度,计算人工抗原的偶联结合比。The coupling effect was identified by UV scanning and SDS-PAGE. The concentrations of heavy metal ions and proteins were determined by ICP-MS and Bradford methods, respectively, and the coupling-binding ratio of artificial antigens was calculated.
紫外扫描方案:OVA、Cu-L1-OVA和Cu-L1配制成浓度为1~5mg·mL-1范围内的溶液,测定200~400nm波长范围内的吸光度,并建立紫外扫描图谱,通过比较每种溶液的吸收曲线来鉴别合成是否成功。Ultraviolet scanning scheme: OVA, Cu-L 1 -OVA and Cu-L 1 were prepared into solutions with a concentration in the range of 1-5 mg·mL -1 , the absorbance in the wavelength range of 200-400 nm was measured, and an ultraviolet scanning spectrum was established. Comparing the absorbance curves of each solution to identify whether the synthesis was successful or not.
紫外扫描图谱中,Cu-L1-OVA溶液与OVA溶液相比,最大吸收波长有变化,说明偶联成功。In the UV scanning spectrum, the maximum absorption wavelength of Cu-L 1 -OVA solution was changed compared with that of OVA solution, indicating that the coupling was successful.
SDS-PAGE电泳方案:选择体积分数为5%浓缩胶,选择体积分数为10%分离胶,上样量10μL每孔,浓缩胶电压75V,分离胶电压100V,考马斯亮蓝染色1h,脱色4次,凝胶成像仪拍照分析。SDS-PAGE electrophoresis scheme: choose 5% stacking gel, choose 10% separating gel, load 10 μL per well, stacking gel voltage 75V, separating gel voltage 100V, Coomassie brilliant blue staining for 1h, destaining 4 times , and the gel imager photographed and analyzed.
经SDS-PAGE显示偶联物电泳条带比单一的蛋白条带有滞后现象,偶联物的分子量比单一蛋白分子量要大,说明偶联成功。SDS-PAGE showed that the electrophoretic band of the conjugate had a hysteresis phenomenon compared with that of the single protein, and the molecular weight of the conjugate was larger than that of the single protein, indicating that the coupling was successful.
通过测定重金属含量和偶联物蛋白浓度计算结合比为21:1。结合比为21:1,则表示一个蛋白分子上结合21个重金属离子。The binding ratio was calculated to be 21:1 by measuring heavy metal content and conjugate protein concentration. The binding ratio is 21:1, which means that 21 heavy metal ions are bound to one protein molecule.
实施例3Example 3
本实施例选用的杂环类双功能螯合剂为L2,替换实施例1中的L1;按照与实施例1相同的步骤制得铜离子人工抗原Cu-L2-BSA,铜离子人工抗原合成路线如图2所示,具体合成步骤如下。The heterocyclic bifunctional chelating agent selected in this example is L 2 , which replaces L 1 in Example 1; the artificial copper ion antigen Cu-L 2 -BSA was prepared according to the same steps as in Example 1, and the copper ion artificial antigen was The synthetic route is shown in Figure 2, and the specific synthetic steps are as follows.
(1)铜离子人工抗原的合成:(1) Synthesis of copper ion artificial antigen:
称取6mg L2,溶解于2mL 0.01mol·L-1、pH 7.4 4-羟乙基哌嗪乙磺酸HEPES溶液,制得L2螯合剂溶液,此溶液为A液;Weigh 6 mg L 2 , dissolve it in 2 mL of 0.01 mol·L -1 , pH 7.4 4-hydroxyethylpiperazineethanesulfonic acid HEPES solution to obtain L 2 chelating agent solution, which is solution A;
称取70.33mg硝酸铜溶解于5mL超纯水中,制得浓度为7.5×10-2mol·L-1的硝酸铜溶液,此溶液为B液;Weigh 70.33 mg of copper nitrate and dissolve it in 5 mL of ultrapure water to prepare a copper nitrate solution with a concentration of 7.5×10 -2 mol·L -1 , which is solution B;
将180μL的B液加入到A液中,室温下避光反应3~5h,此反应液为C液;Add 180 μL of solution B to solution A, and react in the dark for 3 to 5 hours at room temperature. This reaction solution is solution C;
向C液中逐滴加入700μL,20mmol·L-1的戊二醛溶液,室温避光反应过夜,此反应液为D液;Add 700 μL, 20 mmol·L -1 of glutaraldehyde solution dropwise to solution C, react overnight at room temperature in the dark, and this reaction solution is solution D;
称取20mg牛血清白蛋白BSA溶解于3mL HEPES,室温下磁力搅拌混匀,此反应液为E液;Weigh 20 mg of bovine serum albumin BSA, dissolve it in 3 mL of HEPES, and mix with magnetic stirring at room temperature. This reaction solution is E solution;
将D液逐滴加入到E液中,室温下避光反应24h,后逐滴加入150~200μL硼氢化钠溶液(20mg硼氢化钠溶解于200μL超纯水中),室温下避光反应1h;Add solution D to solution E dropwise, react in the dark for 24 hours at room temperature, then add 150-200 μL sodium borohydride solution dropwise (20 mg sodium borohydride dissolved in 200 μL ultrapure water), and react in the dark for 1 hour at room temperature;
反应液先用8KD的透析袋透析3-5次,再用30KD的超滤离心管7000~9000r·min-1离心洗涤3~5次,每次15~20min,用5~10mL的0.01mol·L-1,pH7.4的HEPES溶液复溶,后分装,-20℃低温保存,制得重金属铜人工抗原Cu-L2-BSA,L2表示2-S-(3-氨基苯)-1,4,7三氮杂环壬烷-1,4,7-三乙酸(简写为m-NH2-Bn-NOTA)。The reaction solution was first dialyzed 3-5 times with an 8KD dialysis bag, and then centrifuged and washed 3-5 times with a 30KD ultrafiltration centrifuge tube at 7000-9000 r·min -1 for 15-20 min each time, with 5-10 mL of 0.01 mol· L -1 , reconstituted in HEPES solution with pH 7.4, then packaged and stored at -20℃ to prepare heavy metal copper artificial antigen Cu-L 2 -BSA, L 2 represents 2-S-(3-aminobenzene)- 1,4,7 triazacyclononane-1,4,7-triacetic acid (abbreviated as m- NH2 -Bn-NOTA).
(2)人工抗原的鉴定:(2) Identification of artificial antigens:
采取紫外扫描和SDS-PAGE鉴定其偶联效果,采用ICP-MS法和Bradford法分别测定重金属离子和蛋白浓度,计算人工抗原的偶联结合比。The coupling effect was identified by UV scanning and SDS-PAGE. The concentrations of heavy metal ions and proteins were determined by ICP-MS and Bradford methods, respectively, and the coupling-binding ratio of artificial antigens was calculated.
紫外扫描方案:BSA、Cu-L2-BSA和Cu-L2配制成浓度为1~5mg·mL-1范围内的溶液,测定200~400nm波长范围内的吸光度,并建立紫外扫描图谱,通过比较每种溶液的吸收曲线来鉴别合成是否成功。Ultraviolet scanning scheme: BSA, Cu-L 2 -BSA and Cu-L 2 were prepared into a solution with a concentration in the range of 1-5 mg·mL -1 , the absorbance in the wavelength range of 200-400 nm was measured, and an ultraviolet scanning spectrum was established. Comparing the absorbance curves of each solution to identify whether the synthesis was successful or not.
紫外扫描图谱中,Cu-L2-BSA溶液与BSA溶液相比,最大吸收波长有变化,说明偶联成功。In the UV scanning spectrum, the maximum absorption wavelength of Cu-L 2 -BSA solution was changed compared with that of BSA solution, indicating that the coupling was successful.
SDS-PAGE电泳方案:选择体积分数为5%浓缩胶,选择体积分数为10%分离胶,上样量10μL每孔,浓缩胶电压75V,分离胶电压100V,考马斯亮蓝染色1h,脱色4次,凝胶成像仪拍照分析。SDS-PAGE electrophoresis scheme: choose 5% stacking gel, choose 10% separating gel, load 10 μL per well, stacking gel voltage 75V, separating gel voltage 100V, Coomassie brilliant blue staining for 1h, destaining 4 times , and the gel imager photographed and analyzed.
经SDS-PAGE显示偶联物电泳条带比单一的蛋白条带有滞后现象,偶联物的分子量比单一蛋白分子量要大,说明偶联成功。SDS-PAGE showed that the electrophoretic band of the conjugate had a hysteresis phenomenon compared with that of the single protein, and the molecular weight of the conjugate was larger than that of the single protein, indicating that the coupling was successful.
通过测定重金属含量和偶联物蛋白浓度计算结合比为46:1,偶联效率较高。结合比越高,说明一个蛋白分子上偶联重金属离子的数量越多,偶联效率也越高,结合比为46:1,则表示一个蛋白分子上结合46个重金属离子。The binding ratio was calculated to be 46:1 by measuring the content of heavy metals and the protein concentration of the conjugate, and the coupling efficiency was high. The higher the binding ratio, the greater the number of heavy metal ions coupled to a protein molecule, and the higher the coupling efficiency. When the binding ratio is 46:1, it means that a protein molecule binds 46 heavy metal ions.
实施例4Example 4
本实施例选用的杂环类双功能螯合剂为L2,替换实施例2中的L1;按照与实施例2相同的步骤制得铜离子人工抗原Cu-L2-OVA,铜离子人工抗原合成路线如图2所示,具体合成步骤如下。The heterocyclic bifunctional chelating agent selected in this example is L 2 , which replaces L 1 in Example 2; the artificial copper ion antigen Cu-L 2 -OVA was prepared according to the same steps as in Example 2, and the copper ion artificial antigen was The synthetic route is shown in Figure 2, and the specific synthetic steps are as follows.
(1)铜离子人工抗原的合成:(1) Synthesis of copper ion artificial antigen:
称取7mg L2,溶解于2mL 0.01mol·L-1、pH7.4 4-羟乙基哌嗪乙磺酸HEPES溶液,制得L2螯合剂溶液,此溶液为A液;Weigh 7 mg L 2 , dissolve it in 2 mL of 0.01 mol·L -1 , pH7.4 4-hydroxyethylpiperazineethanesulfonic acid HEPES solution to obtain L 2 chelating agent solution, which is solution A;
称取70.33mg硝酸铜溶解于5mL超纯水中,制得浓度为7.5×10-2mol·L-1的硝酸铜溶液,此溶液为B液;Weigh 70.33 mg of copper nitrate and dissolve it in 5 mL of ultrapure water to prepare a copper nitrate solution with a concentration of 7.5×10 -2 mol·L -1 , which is solution B;
将195μL的B液加入到A液中,室温下避光反应3~5h,此反应液为C液;Add 195 μL of solution B to solution A, and react in the dark for 3 to 5 hours at room temperature. This reaction solution is solution C;
向C液中逐滴加入720μL,20mmol·L-1的戊二醛溶液,室温避光反应过夜,此反应液为D液;Add 720 μL, 20 mmol·L -1 of glutaraldehyde solution dropwise to solution C, and react overnight in the dark at room temperature. This reaction solution is solution D;
称取20mg鸡卵清蛋白OVA溶解于3mL HEPES,室温下磁力搅拌混匀,此反应液为E液;Weigh 20 mg of chicken ovalbumin OVA and dissolve it in 3 mL of HEPES, and mix with magnetic stirring at room temperature. This reaction solution is E solution;
将D液逐滴加入到E液中,室温下避光反应24h,后逐滴加入150~200μL硼氢化钠溶液(20mg硼氢化钠溶解于200μL超纯水中),室温下避光反应1h;Add solution D to solution E dropwise, react in the dark for 24 hours at room temperature, then add 150-200 μL sodium borohydride solution dropwise (20 mg sodium borohydride dissolved in 200 μL ultrapure water), and react in the dark for 1 hour at room temperature;
反应液先用8KD的透析袋透析3-5次,再用30KD的超滤离心管7000~9000r·min-1离心洗涤3~5次,每次15~20min,用5~10mL的0.01mol·L-1,pH7.4的HEPES溶液复溶,后分装,-20℃低温保存,制得重金属铜人工抗原Cu-L2-OVA,L2表示2-S-(3-氨基苯)-1,4,7三氮杂环壬烷-1,4,7-三乙酸(简写为m-NH2-Bn-NOTA)。The reaction solution was first dialyzed 3-5 times with an 8KD dialysis bag, and then centrifuged and washed 3-5 times with a 30KD ultrafiltration centrifuge tube at 7000-9000 r·min -1 for 15-20 min each time, with 5-10 mL of 0.01 mol· L -1 , reconstituted in HEPES solution with pH 7.4, then packaged and stored at -20 ℃ to prepare heavy metal copper artificial antigen Cu-L 2 -OVA, L 2 represents 2-S-(3-aminobenzene)- 1,4,7 triazacyclononane-1,4,7-triacetic acid (abbreviated as m- NH2 -Bn-NOTA).
(2)人工抗原的鉴定:(2) Identification of artificial antigens:
采取紫外扫描和SDS-PAGE鉴定其偶联效果,采用ICP-MS法和Bradford法分别测定重金属离子和蛋白浓度,计算人工抗原的偶联结合比。The coupling effect was identified by UV scanning and SDS-PAGE. The concentrations of heavy metal ions and proteins were determined by ICP-MS and Bradford methods, respectively, and the coupling-binding ratio of artificial antigens was calculated.
紫外扫描方案:OVA、Cu-L2-OVA和Cu-L2配制成浓度为1~5mg·mL-1的溶液,测定200~400nm波长范围内的吸光度,并建立紫外扫描图谱,通过比较每种溶液的吸收曲线来鉴别合成是否成功。Ultraviolet scanning scheme: OVA, Cu-L 2 -OVA and Cu-L 2 were prepared into a solution with a concentration of 1-5 mg·mL -1 , the absorbance in the wavelength range of 200-400 nm was measured, and an ultraviolet scanning spectrum was established. The absorption curve of the solution was used to identify whether the synthesis was successful.
紫外扫描图谱中,Cu-L2-OVA溶液与OVA溶液相比,最大吸收波长有变化,说明偶联成功。In the UV scanning spectrum, the maximum absorption wavelength of Cu-L 2 -OVA solution was changed compared with that of OVA solution, indicating that the coupling was successful.
SDS-PAGE电泳方案:选择体积分数为5%浓缩胶,选择体积分数为10%分离胶,上样量10μL每孔,浓缩胶电压75V,分离胶电压100V,考马斯亮蓝染色1h,脱色4次,凝胶成像仪拍照分析。SDS-PAGE electrophoresis scheme: choose 5% stacking gel, choose 10% separating gel, load 10 μL per well, stacking gel voltage 75V, separating gel voltage 100V, Coomassie brilliant blue staining for 1h, destaining 4 times , and the gel imager photographed and analyzed.
经SDS-PAGE显示偶联物电泳条带比单一的蛋白条带有滞后现象,偶联物的分子量比单一蛋白分子量要大,说明偶联成功。SDS-PAGE showed that the electrophoretic band of the conjugate had a hysteresis phenomenon compared with that of the single protein, and the molecular weight of the conjugate was larger than that of the single protein, indicating that the coupling was successful.
通过测定重金属含量和偶联物蛋白浓度计算结合比为40:1,结合比为40:1则表示一个蛋白分子上结合40个重金属离子。The binding ratio of 40:1 was calculated by measuring the heavy metal content and the conjugated protein concentration, and a binding ratio of 40:1 means that 40 heavy metal ions are bound to one protein molecule.
实施例5Example 5
本实施例选用的杂环类双功能螯合剂为L3,替换实施例1中的L1;按照与实施例1相同的步骤制得铜离子人工抗原Cu-L3-BSA,铜离子人工抗原合成路线如图3所示,具体合成步骤如下。The heterocyclic bifunctional chelating agent selected in this example is L 3 , which replaces L 1 in Example 1; the artificial copper ion antigen Cu-L 3 -BSA was prepared according to the same steps as in Example 1, and the copper ion artificial antigen was The synthetic route is shown in Figure 3, and the specific synthetic steps are as follows.
(1)铜离子人工抗原的合成:(1) Synthesis of copper ion artificial antigen:
称取6mg L3,溶解于2mL 0.01mol·L-1、pH 7.4 4-羟乙基哌嗪乙磺酸HEPES溶液,制得L3螯合剂溶液,此溶液为A液;Weigh 6 mg L 3 , dissolve it in 2 mL of 0.01 mol·L -1 , pH 7.4 4-hydroxyethylpiperazineethanesulfonic acid HEPES solution to obtain L 3 chelating agent solution, which is solution A;
称取70.33mg硝酸铜溶解于5mL超纯水中,制得浓度为7.5×10-2mol·L-1的硝酸铜溶液,此溶液为B液;Weigh 70.33 mg of copper nitrate and dissolve it in 5 mL of ultrapure water to prepare a copper nitrate solution with a concentration of 7.5×10 -2 mol·L -1 , which is solution B;
将180μL的B液加入到A液中,室温下避光反应3~5h,此反应液为C液;Add 180 μL of solution B to solution A, and react in the dark for 3 to 5 hours at room temperature. This reaction solution is solution C;
向C液中逐滴加入700μL,20mmol·L-1的戊二醛溶液,室温避光反应过夜,此反应液为D液;Add 700 μL, 20 mmol·L -1 of glutaraldehyde solution dropwise to solution C, react overnight at room temperature in the dark, and this reaction solution is solution D;
称取20mg牛血清白蛋白BSA溶解于3mL HEPES,室温下磁力搅拌混匀,此反应液为E液;Weigh 20 mg of bovine serum albumin BSA, dissolve it in 3 mL of HEPES, and mix with magnetic stirring at room temperature. This reaction solution is E solution;
将D液逐滴加入到E液中,室温下避光反应24h,后逐滴加入150~200μL硼氢化钠溶液(20mg硼氢化钠溶解于200μL超纯水中),室温下避光反应1h;Add solution D to solution E dropwise, react in the dark for 24 hours at room temperature, then add 150-200 μL sodium borohydride solution dropwise (20 mg sodium borohydride dissolved in 200 μL ultrapure water), and react in the dark for 1 hour at room temperature;
反应液先用8KD的透析袋透析3~5次,再用30KD的超滤离心管7000~9000r·min-1离心洗涤3~5次,每次15~20min,用5~10mL的0.01mol·L-1,pH7.4的HEPES溶液复溶,后分装,-20℃低温保存,制得重金属铜人工抗原Cu-L3-BSA,L3表示2-S-(4-氨基苯)-1,4,7三氮杂环壬烷-1,4,7-三乙酸(简写为p-NH2-Bn-NOTA)。The reaction solution was first dialyzed with an 8KD dialysis bag for 3 to 5 times, and then centrifuged with a 30KD ultrafiltration centrifuge tube at 7000 to 9000 r·min -1 for 3 to 5 times, 15 to 20 minutes each time, with 5 to 10 mL of 0.01 mol· L -1 , reconstituted in HEPES solution with pH 7.4, then packaged and stored at -20 ℃ to prepare heavy metal copper artificial antigen Cu-L 3 -BSA, L 3 represents 2-S-(4-aminobenzene)- 1,4,7 triazacyclononane-1,4,7-triacetic acid (abbreviated as p- NH2 -Bn-NOTA).
(2)人工抗原的鉴定:(2) Identification of artificial antigens:
采取紫外扫描和SDS-PAGE鉴定其偶联效果,采用ICP-MS法和Bradford法分别测定重金属离子和蛋白浓度,计算人工抗原的偶联结合比。The coupling effect was identified by UV scanning and SDS-PAGE. The concentrations of heavy metal ions and proteins were determined by ICP-MS and Bradford methods, respectively, and the coupling-binding ratio of artificial antigens was calculated.
紫外扫描方案:BSA、Cu-L3-BSA和Cu-L3配制成浓度为1~5mg·mL-1范围内的溶液,测定200~400nm波长范围内的吸光度,并建立紫外扫描图谱,通过比较每种溶液的吸收曲线来鉴别合成是否成功。Ultraviolet scanning scheme: BSA, Cu-L 3 -BSA and Cu-L 3 were prepared into a solution with a concentration in the range of 1-5 mg·mL -1 , the absorbance in the wavelength range of 200-400 nm was measured, and an ultraviolet scanning spectrum was established. Comparing the absorbance curves of each solution to identify whether the synthesis was successful or not.
紫外扫描图谱中,Cu-L3-BSA溶液与BSA溶液相比,最大吸收波长有变化,说明偶联成功。In the UV scanning spectrum, the maximum absorption wavelength of Cu-L 3 -BSA solution was changed compared with that of BSA solution, indicating that the coupling was successful.
SDS-PAGE电泳方案:选择体积分数为5%浓缩胶,选择体积分数为10%分离胶,上样量10μL每孔,浓缩胶电压75V,分离胶电压100V,考马斯亮蓝染色1h,脱色4次,凝胶成像仪拍照分析。SDS-PAGE electrophoresis scheme: choose 5% stacking gel, choose 10% separating gel, load 10 μL per well, stacking gel voltage 75V, separating gel voltage 100V, Coomassie brilliant blue staining for 1h, destaining 4 times , and the gel imager photographed and analyzed.
经SDS-PAGE显示偶联物电泳条带比单一的蛋白条带有滞后现象,偶联物的分子量比单一蛋白分子量要大,说明偶联成功。SDS-PAGE showed that the electrophoretic band of the conjugate had a hysteresis phenomenon compared with that of the single protein, and the molecular weight of the conjugate was larger than that of the single protein, indicating that the coupling was successful.
通过测定重金属含量和偶联物蛋白浓度计算结合比为39:1,结合比为39:1,则表示一个蛋白分子上结合39个重金属离子。By measuring the heavy metal content and the conjugated protein concentration, the binding ratio was calculated to be 39:1, and the binding ratio was 39:1, which indicated that 39 heavy metal ions were bound to one protein molecule.
实施例6Example 6
本实施例选用的杂环类双功能螯合剂为L3,替换实施例1中的L1;按照与实施例2相同的步骤制得铜离子人工抗原Cu-L3-OVA,铜离子人工抗原合成路线如图3所示,具体合成步骤如下。The heterocyclic bifunctional chelating agent selected in this example is L 3 , which replaces L 1 in Example 1 ; the artificial copper ion antigen Cu-L 3 -OVA was prepared according to the same steps as in Example 2, and the copper ion artificial antigen was The synthetic route is shown in Figure 3, and the specific synthetic steps are as follows.
(1)铜离子人工抗原的合成:(1) Synthesis of copper ion artificial antigen:
称取7mg L3,溶解于2mL 0.01mol·L-1、pH 7.4 4-羟乙基哌嗪乙磺酸HEPES溶液,制得L3螯合剂溶液,此溶液为A液;Weigh 7 mg L 3 , dissolve it in 2 mL of 0.01 mol·L -1 , pH 7.4 4-hydroxyethylpiperazineethanesulfonic acid HEPES solution to obtain L 3 chelating agent solution, which is solution A;
称取70.33mg硝酸铜溶解于5mL超纯水中,制得浓度为7.5×10-2mol·L-1的硝酸铜溶液,此溶液为B液;Weigh 70.33 mg of copper nitrate and dissolve it in 5 mL of ultrapure water to prepare a copper nitrate solution with a concentration of 7.5×10 -2 mol·L -1 , which is solution B;
将195μL的B液加入到A液中,室温下避光反应3~5h,此反应液为C液;Add 195 μL of solution B to solution A, and react in the dark for 3 to 5 hours at room temperature. This reaction solution is solution C;
向C液中逐滴加入720μL,20mmol·L-1的戊二醛溶液,室温避光反应过夜,此反应液为D液;Add 720 μL, 20 mmol·L -1 of glutaraldehyde solution dropwise to solution C, and react overnight in the dark at room temperature. This reaction solution is solution D;
称取20mg鸡卵清蛋白OVA溶解于3mL HEPES,室温下磁力搅拌混匀,此反应液为E液;Weigh 20 mg of chicken ovalbumin OVA and dissolve it in 3 mL of HEPES, and mix with magnetic stirring at room temperature. This reaction solution is E solution;
将D液逐滴加入到E液中,室温下避光反应24h,后逐滴加入150~200μL硼氢化钠溶液(20mg硼氢化钠溶解于200μL超纯水中),室温下避光反应1h;Add solution D to solution E dropwise, react in the dark for 24 hours at room temperature, then add 150-200 μL sodium borohydride solution dropwise (20 mg sodium borohydride dissolved in 200 μL ultrapure water), and react in the dark for 1 hour at room temperature;
反应液先用8KD的透析袋透析3~5次,再用30KD的超滤离心管7000~9000r·min-1离心洗涤3~5次,每次15~20min,用5~10mL的0.01mol·L-1,pH 7.4的HEPES溶液复溶,后分装,-20℃低温保存,制得重金属铜人工抗原Cu-L3-OVA,L3表示2-S-(4-氨基苯)-1,4,7三氮杂环壬烷-1,4,7-三乙酸(简写为p-NH2-Bn-NOTA)。The reaction solution was first dialyzed with an 8KD dialysis bag for 3 to 5 times, and then centrifuged with a 30KD ultrafiltration centrifuge tube at 7000 to 9000 r·min -1 for 3 to 5 times, 15 to 20 minutes each time, with 5 to 10 mL of 0.01 mol· L -1 , reconstituted in HEPES solution with pH 7.4, then packaged and stored at -20 ℃ to prepare heavy metal copper artificial antigen Cu-L 3 -OVA, L 3 represents 2-S-(4-aminobenzene)-1 , 4,7 triazacyclononane-1,4,7-triacetic acid (abbreviated as p- NH2 -Bn-NOTA).
(2)人工抗原的鉴定:(2) Identification of artificial antigens:
采取紫外扫描和SDS-PAGE鉴定其偶联效果,采用ICP-MS法和Bradford法分别测定重金属离子和蛋白浓度,计算人工抗原的偶联结合比。The coupling effect was identified by UV scanning and SDS-PAGE. The concentrations of heavy metal ions and proteins were determined by ICP-MS and Bradford methods, respectively, and the coupling-binding ratio of artificial antigens was calculated.
紫外扫描方案:OVA、Cu-L3-OVA和Cu-L3配制成浓度为1~5mg·mL-1范围内的溶液,测定200~400nm波长范围内的吸光度,并建立紫外扫描图谱,通过比较每种溶液的吸收曲线来鉴别合成是否成功。UV scanning scheme: OVA, Cu-L 3 -OVA and Cu-L 3 were prepared into solutions with a concentration in the range of 1 to 5 mg·mL -1 , the absorbance in the wavelength range of 200 to 400 nm was measured, and the UV scanning spectrum was established. Comparing the absorbance curves of each solution to identify whether the synthesis was successful or not.
紫外扫描图谱中,Cu-L3-OVA溶液与OVA溶液相比,最大吸收波长有变化,说明偶联成功。In the UV scanning spectrum, the maximum absorption wavelength of Cu-L 3 -OVA solution was changed compared with that of OVA solution, indicating that the coupling was successful.
SDS-PAGE电泳方案:选择体积分数为5%浓缩胶,选择体积分数为10%分离胶,上样量10μL每孔,浓缩胶电压75V,分离胶电压100V,考马斯亮蓝染色1h,脱色4次,凝胶成像仪拍照分析。SDS-PAGE electrophoresis scheme: choose 5% stacking gel, choose 10% separating gel, load 10 μL per well, stacking gel voltage 75V, separating gel voltage 100V, Coomassie brilliant blue staining for 1h, destaining 4 times , and the gel imager photographed and analyzed.
经SDS-PAGE显示偶联物电泳条带比单一的蛋白条带有滞后现象,偶联物的分子量比单一蛋白分子量要大,说明偶联成功。SDS-PAGE showed that the electrophoretic band of the conjugate had a hysteresis phenomenon compared with that of the single protein, and the molecular weight of the conjugate was larger than that of the single protein, indicating that the coupling was successful.
通过测定重金属含量和偶联物蛋白浓度计算结合比为36:1,结合比为36:1,则表示一个蛋白分子上结合36个重金属离子。By measuring the heavy metal content and the conjugate protein concentration, the binding ratio was calculated to be 36:1, and the binding ratio was 36:1, which indicated that 36 heavy metal ions were bound to one protein molecule.
实施例7Example 7
本实施例选用的杂环类双功能螯合剂为L4,替换实施例1中的L1;按照与实施例1相同的步骤制得铜离子人工抗原Cu-L4-BSA,铜离子人工抗原合成路线如图4所示,具体合成步骤如下。The heterocyclic bifunctional chelating agent selected in this example is L 4 , which replaces L 1 in Example 1; the artificial copper ion antigen Cu-L 4 -BSA was prepared according to the same steps as in Example 1, and the copper ion artificial antigen was The synthetic route is shown in Figure 4, and the specific synthetic steps are as follows.
(1)铜离子人工抗原的合成:(1) Synthesis of copper ion artificial antigen:
称取6mg L4,溶解于2mL 0.01mol·L-1、pH7.4 4-羟乙基哌嗪乙磺酸HEPES溶液,制得L4螯合剂溶液,此溶液为A液;Weigh 6 mg L 4 , dissolve it in 2 mL of 0.01 mol·L -1 , pH7.4 4-hydroxyethylpiperazineethanesulfonic acid HEPES solution to obtain L 4 chelating agent solution, which is solution A;
称取70.33mg硝酸铜溶解于5mL超纯水中,制得浓度为7.5×10-2mol·L-1的硝酸铜溶液,此溶液为B液;Weigh 70.33 mg of copper nitrate and dissolve it in 5 mL of ultrapure water to prepare a copper nitrate solution with a concentration of 7.5×10 -2 mol·L -1 , which is solution B;
将180μL的B液加入到A液中,室温下避光反应3~5h,此反应液为C液;Add 180 μL of solution B to solution A, and react in the dark for 3 to 5 hours at room temperature. This reaction solution is solution C;
向C液中逐滴加入700μL,20mmol·L-1的戊二醛溶液,室温避光反应过夜,此反应液为D液;Add 700 μL, 20 mmol·L -1 of glutaraldehyde solution dropwise to solution C, react overnight at room temperature in the dark, and this reaction solution is solution D;
称取20mg牛血清白蛋白BSA溶解于3mL HEPES,室温下磁力搅拌混匀,此反应液为E液;Weigh 20 mg of bovine serum albumin BSA, dissolve it in 3 mL of HEPES, and mix with magnetic stirring at room temperature. This reaction solution is E solution;
将D液逐滴加入到E液中,室温下避光反应24h,后逐滴加入150~200μL硼氢化钠溶液(20mg溶解于200μL超纯水中),室温下避光反应1h;Add solution D to solution E dropwise, react in the dark for 24 hours at room temperature, then add 150-200 μL sodium borohydride solution (20 mg dissolved in 200 μL ultrapure water) dropwise, and react in the dark for 1 hour at room temperature;
反应液先用8KD的透析袋透析3~5次,再用30KD的超滤离心管7000~9000r·min-1离心洗涤3~5次,每次15~20min,用5~10mL的0.01mol·L-1,pH7.4的HEPES溶液复溶,后分装,-20℃低温保存,制得重金属铜人工抗原Cu-L4-BSA,L4表示2-S-[4-(3-氨基丙基)-苯]-1,4,7三氮杂环壬烷-1,4,7-三乙酸(简写为p-CH2CH2CH2NH2-Bn-NOTA)。The reaction solution was first dialyzed with an 8KD dialysis bag for 3 to 5 times, and then centrifuged with a 30KD ultrafiltration centrifuge tube at 7000 to 9000 r·min -1 for 3 to 5 times, 15 to 20 minutes each time, with 5 to 10 mL of 0.01 mol· L -1 , reconstituted in HEPES solution with pH 7.4, then packaged and stored at -20 ℃ to prepare heavy metal copper artificial antigen Cu-L 4 -BSA, L 4 represents 2-S-[4-(3-amino propyl)-benzene] -1,4,7 triazacyclononane - 1,4,7-triacetic acid (abbreviated as p- CH2CH2CH2NH2 - Bn-NOTA).
(2)人工抗原的鉴定:(2) Identification of artificial antigens:
采取紫外扫描和SDS-PAGE鉴定其偶联效果,采用ICP-MS法和Bradford法分别测定重金属离子和蛋白浓度,计算人工抗原的偶联结合比。The coupling effect was identified by UV scanning and SDS-PAGE. The concentrations of heavy metal ions and proteins were determined by ICP-MS and Bradford methods, respectively, and the coupling-binding ratio of artificial antigens was calculated.
紫外扫描方案:BSA、Cu-L4-BSA和Cu-L4配制成浓度为1~5mg·mL-1范围内的溶液,测定200~400nm波长范围内的吸光度,并建立紫外扫描图谱,通过比较每种溶液的吸收曲线来鉴别合成是否成功。Ultraviolet scanning scheme: BSA, Cu-L 4 -BSA and Cu-L 4 were prepared into solutions with a concentration in the range of 1 to 5 mg·mL -1 , the absorbance in the wavelength range of 200 to 400 nm was measured, and an ultraviolet scanning spectrum was established. Comparing the absorbance curves of each solution to identify whether the synthesis was successful or not.
紫外扫描图谱中,Cu-L4-BSA溶液与BSA溶液相比,最大吸收波长有变化,说明偶联成功。In the UV scanning spectrum, the maximum absorption wavelength of Cu-L 4 -BSA solution was changed compared with that of BSA solution, indicating that the coupling was successful.
SDS-PAGE电泳方案:选择体积分数为5%浓缩胶,选择体积分数为10%分离胶,上样量10μL每孔,浓缩胶电压75V,分离胶电压100V,考马斯亮蓝染色1h,脱色4次,凝胶成像仪拍照分析。SDS-PAGE electrophoresis scheme: choose 5% stacking gel, choose 10% separating gel, load 10 μL per well, stacking gel voltage 75V, separating gel voltage 100V, Coomassie brilliant blue staining for 1h, destaining 4 times , and the gel imager photographed and analyzed.
经SDS-PAGE显示偶联物电泳条带比单一的蛋白条带有滞后现象,偶联物的分子量比单一蛋白分子量要大,说明偶联成功。SDS-PAGE showed that the electrophoretic band of the conjugate had a hysteresis phenomenon compared with that of the single protein, and the molecular weight of the conjugate was larger than that of the single protein, indicating that the coupling was successful.
通过测定重金属含量和偶联物蛋白浓度计算结合比为42:1,结合比为42:1,则表示一个蛋白分子上结合42个重金属离子。By measuring the heavy metal content and the conjugated protein concentration, the binding ratio was calculated to be 42:1, and the binding ratio was 42:1, indicating that 42 heavy metal ions were bound to one protein molecule.
实施例8Example 8
本实施例选用的杂环类双功能螯合剂为L4,替换实施例1中的L1;按照与实施例2相同的步骤制得铜离子人工抗原Cu-L4-OVA,铜离子人工抗原合成路线如图4所示,具体合成步骤如下。The heterocyclic bifunctional chelating agent selected in this example is L 4 , which replaces L 1 in Example 1 ; the artificial copper ion antigen Cu-L 4 -OVA was prepared according to the same steps as in Example 2, and the copper ion artificial antigen was The synthetic route is shown in Figure 4, and the specific synthetic steps are as follows.
(1)铜离子人工抗原的合成:(1) Synthesis of copper ion artificial antigen:
称取7mg L4,溶解于2mL 0.01mol·L-1、pH 7.4 4-羟乙基哌嗪乙磺酸HEPES溶液,制得L4螯合剂溶液,此溶液为A液;Weigh 7 mg L 4 , dissolve it in 2 mL of 0.01 mol·L -1 , pH 7.4 4-hydroxyethylpiperazineethanesulfonic acid HEPES solution to obtain L 4 chelating agent solution, which is solution A;
称取70.33mg硝酸铜溶解于5mL超纯水中,制得浓度为7.5×10-2mol·L-1的硝酸铜溶液,此溶液为B液;Weigh 70.33 mg of copper nitrate and dissolve it in 5 mL of ultrapure water to prepare a copper nitrate solution with a concentration of 7.5×10 -2 mol·L -1 , which is solution B;
将195μL的B液加入到A液中,室温下避光反应3~5h,此反应液为C液;Add 195 μL of solution B to solution A, and react in the dark for 3 to 5 hours at room temperature. This reaction solution is solution C;
向C液中逐滴加入720μL,20mmol·L-1的戊二醛溶液,室温避光反应过夜,此反应液为D液;Add 720 μL, 20 mmol·L -1 of glutaraldehyde solution dropwise to solution C, and react overnight in the dark at room temperature. This reaction solution is solution D;
称取20mg鸡卵清蛋白OVA溶解于4mL HEPES,室温下磁力搅拌混匀,此反应液为E液;Weigh 20 mg of chicken ovalbumin OVA and dissolve it in 4 mL of HEPES, and mix with magnetic stirring at room temperature. This reaction solution is E solution;
将D液逐滴加入到E液中,室温下避光反应24h,后逐滴加入150~200μl硼氢化钠溶液(20mg溶解于200μl超纯水中),室温下避光反应1h;Add solution D to solution E dropwise, react in the dark for 24 hours at room temperature, then add 150-200 μl sodium borohydride solution (20 mg dissolved in 200 μl ultrapure water) dropwise, and react in the dark for 1 hour at room temperature;
反应液先用8KD的透析袋透析3~5次,再用30KD的超滤离心管7000~9000r·min-1离心洗涤3~5次,每次15~20min,用5~10mL的0.01mol·L-1,pH 7.4的HEPES溶液复溶,后分装,-20℃低温保存,制得重金属铜人工抗原Cu-L4-OVA,L4表示2-S-[4-(3-氨基丙基)-苯]-1,4,7三氮杂环壬烷-1,4,7-三乙酸(简称p-CH2CH2CH2NH2-Bn-NOTA)。The reaction solution was first dialyzed with an 8KD dialysis bag for 3 to 5 times, and then centrifuged with a 30KD ultrafiltration centrifuge tube at 7000 to 9000 r·min -1 for 3 to 5 times, 15 to 20 minutes each time, with 5 to 10 mL of 0.01 mol· L -1 , reconstituted in HEPES solution with pH 7.4, then packaged and stored at -20 ℃ to prepare heavy metal copper artificial antigen Cu-L 4 -OVA, L 4 represents 2-S-[4-(3-aminopropane) base)-benzene] -1,4,7 triazacyclononane - 1,4,7-triacetic acid (abbreviated as p- CH2CH2CH2NH2 - Bn-NOTA).
(2)人工抗原的鉴定:(2) Identification of artificial antigens:
采取紫外扫描和SDS-PAGE鉴定其偶联效果,采用ICP-MS法和Bradford法分别测定重金属离子和蛋白浓度,计算人工抗原的偶联结合比。The coupling effect was identified by UV scanning and SDS-PAGE. The concentrations of heavy metal ions and proteins were determined by ICP-MS and Bradford methods, respectively, and the coupling-binding ratio of artificial antigens was calculated.
紫外扫描方案:OVA、Cu-L4-OVA和Cu-L4配制成浓度为1~5mg·mL-1范围内的溶液,测定200~400nm波长范围内的吸光度,并建立紫外扫描图谱,通过比较每种溶液的吸收曲线来鉴别合成是否成功。Ultraviolet scanning scheme: OVA, Cu-L 4 -OVA and Cu-L 4 were prepared into solutions with a concentration in the range of 1-5 mg·mL -1 , the absorbance in the wavelength range of 200-400 nm was measured, and an ultraviolet scanning spectrum was established. Comparing the absorbance curves of each solution to identify whether the synthesis was successful or not.
紫外扫描图谱中,Cu-L4-OVA溶液与OVA溶液相比,最大吸收波长有变化,说明偶联成功。In the UV scanning spectrum, the maximum absorption wavelength of Cu-L 4 -OVA solution was changed compared with that of OVA solution, indicating that the coupling was successful.
SDS-PAGE电泳方案:选择体积分数为5%浓缩胶,选择体积分数为10%分离胶,上样量10μL每孔,浓缩胶电压75V,分离胶电压100V,考马斯亮蓝染色1h,脱色4次,凝胶成像仪拍照分析。SDS-PAGE electrophoresis program: choose 5% stacking gel, choose 10% separating gel, load 10 μL per well, stacking gel voltage 75V, separating gel voltage 100V, Coomassie brilliant blue staining for 1h, destaining 4 times , and the gel imager photographed and analyzed.
经SDS-PAGE显示偶联物电泳条带比单一的蛋白条带有滞后现象,偶联物的分子量比单一蛋白分子量要大,说明偶联成功。SDS-PAGE showed that the electrophoretic band of the conjugate had a hysteresis phenomenon compared with that of the single protein, and the molecular weight of the conjugate was larger than that of the single protein, indicating that the coupling was successful.
通过测定重金属含量和偶联物蛋白浓度计算结合比为38:1,结合比为38:1,则表示一个蛋白分子上结合38个重金属离子。By measuring the heavy metal content and the conjugated protein concentration, the binding ratio was calculated to be 38:1, and the binding ratio was 38:1, indicating that 38 heavy metal ions were bound to one protein molecule.
实施例9Example 9
抗血清效价的测定:Determination of antiserum titer:
将实施例1、3、5和7制备的人工抗原分别对BALB/C小鼠进行免疫,初次免疫采用弗氏完全佐剂乳化人工抗原,乳化后,注射,计量为250μg/小鼠,后每间隔21d加强免疫,共加强免疫3次,加强免疫采用不完全佐剂进行乳化,免疫计量为150μg/小鼠,加强免疫14d后小鼠断尾采血进行多抗血清的效价测定,血清用封闭液倍比稀释后ELISA法测定抗血清效价,以免疫之前的小鼠血清为阴性对照,以阳性血清OD450nm值与阴性血清OD450nm值比值大于2.1所在稀释度为抗血清效价,结果如表1所示。最后进行末免,末免采用人工抗原直接腹腔注射的方式进行,免疫计量为300μg/小鼠。The artificial antigens prepared in Examples 1, 3, 5 and 7 were respectively immunized to BALB/C mice, and the artificial antigen was emulsified with Freund's complete adjuvant for the initial immunization. The immunization was boosted at intervals of 21 days, and the booster immunization was boosted 3 times in total. The booster immunization was emulsified with incomplete adjuvant, and the immunization dose was 150 μg/mouse. The titer of antiserum was determined by ELISA after doubling the dilution. The mouse serum before immunization was used as the negative control, and the dilution at which the ratio of the OD 450nm value of the positive serum to the OD 450nm value of the negative serum was greater than 2.1 was the antiserum titer. The results are as follows: shown in Table 1. Finally, the final immunization was performed by direct intraperitoneal injection of artificial antigen, and the immunization dose was 300 μg/mouse.
效价测定采用间接ELISA方法,具体实验步骤如下:The titer was determined by an indirect ELISA method, and the specific experimental steps were as follows:
a.包被:分别以实施例2或者实施例4或者实施例6或者实施例8中的人工抗原为包被原,pH 9.6,0.05mol·L-1CBS为包被缓冲液,包被原浓度为10μg·mL-1,包被量为100μL/孔,37℃中包被2h,后PBST洗液洗板4次;a. Coating: Take the artificial antigen in Example 2 or Example 4 or Example 6 or Example 8 as the coating original, pH 9.6, 0.05mol·L -1 CBS as the coating buffer, and the coating original The concentration was 10 μg·mL -1 , the coating amount was 100 μL/well, and the plate was coated for 2 hours at 37°C, and then the plate was washed 4 times with PBST washing solution;
b.封闭:加入封闭液250μL/孔,37℃孵育30min后,PBST洗液洗板4次;b. Blocking: Add 250 μL/well of blocking solution, incubate at 37°C for 30 min, and wash the plate 4 times with PBST washing solution;
c.加抗血清:将小鼠采血获得的抗血清10000r·min-1离心5min后,吸取10μL加入到2mL封闭液,(起始稀释倍数为200倍),后采用封闭液倍比稀释11个梯度和1个阴性对照,100μL/孔,每个梯度4个重复,37℃孵育1h,后采用PBST洗液洗板4次;c. Add antiserum: After centrifuging the antiserum obtained by blood collection of mice at 10000r·min -1 for 5 minutes, draw 10 μL into 2mL blocking solution (the initial dilution ratio is 200 times), and then use the blocking solution to dilute 11 times. Gradient and 1 negative control, 100 μL/well, 4 replicates for each gradient, incubated at 37°C for 1 h, and then washed 4 times with PBST wash solution;
d.加酶标二抗:反应结束后PBST洗板4次,HRP标记的羊抗鼠二抗10000倍稀释后加入酶标板,100μL/孔,37℃孵育1h,后PBST洗液洗板4次;d. Add enzyme-labeled secondary antibody: after the reaction, wash the plate 4 times with PBST, and add the HRP-labeled goat anti-mouse secondary antibody 10,000 times to the enzyme-labeled plate, 100 μL/well, incubate at 37 °C for 1 h, and then wash the plate with PBST washing solution 4. Second-rate;
e.加底物反应液:加入TMB底物缓冲液,100μL/孔,37℃孵育15min;e. Add substrate reaction solution: add TMB substrate buffer, 100μL/well, incubate at 37°C for 15min;
f.终止读数:加入2mol·L-1硫酸50μL/孔,用酶标仪读取OD450nm值。f. Stop reading: add 50 μL/well of 2 mol·L -1 sulfuric acid, and read the OD 450nm value with a microplate reader.
表1实施例1-8中的结合比与抗血清效价测定结果Binding ratio and antiserum titer determination results in Table 1 Examples 1-8
由表1的结合比与抗血清效价测定结果表明,抗血清效价高低顺序为:实施例3>实施例7>实施例5>实施例1,结合比高低顺序为:实施例3>实施例7>实施例5>实施例1,其中,实施例3的抗血清效价最高,实施例7的抗血清效价仅低于实施例3。这说明实施例3中制备的铜离子人工抗原Cu-L2-BSA能更好的把重金属抗原决定簇表现出来,抗原特异性较强,同时实施例3和实施例7所制备的人工抗原其结合比较高,高结合比更容易引发强烈的免疫应答反应,有利于制备抗重金属铜离子单克隆抗体。The results of the determination of the binding ratio and antiserum titer in Table 1 show that the order of antiserum titer is: Example 3> Example 7> Example 5> Example 1, and the order of binding ratio is: Example 3> Implementation Example 7>Example 5>Example 1, wherein, the antiserum titer of Example 3 is the highest, and the antiserum titer of Example 7 is only lower than that of Example 3. This shows that the copper ion artificial antigen Cu-L 2 -BSA prepared in Example 3 can better express the heavy metal antigenic determinant, and the antigen specificity is stronger. At the same time, the artificial antigen prepared in Example 3 and Example 7 has The binding ratio is high, and the high binding ratio is more likely to trigger a strong immune response, which is beneficial to the preparation of anti-heavy metal copper ion monoclonal antibodies.
实施例1、3、5、7采用的具体制备方法、测定方法相同,但是,采用的双功能螯合剂不同,分别为:o-NH2-Bn-NOTA,m-NH2-Bn-NOTA,p-NH2-Bn-NOTA,p-CH2CH2CH2NH2-Bn-NOTA。这说明螯合剂中-NH2处于苯环的间位,螯合剂m-NH2-Bn-NOTA结合重金属离子后,在空间结构上能更好地将重金属铜离子的结构展现出来,而且从实验结果看,间位结构制备的人工抗原的结合比也最高,作为抗原决定簇,更有利于制备亲和力和灵敏度更高、特异性更强的抗重金属单克隆抗体。The specific preparation methods and measurement methods adopted in Examples 1, 3, 5, and 7 are the same, but the bifunctional chelating agents adopted are different, namely: o-NH 2 -Bn-NOTA, m-NH 2 -Bn-NOTA, p - NH2 - Bn-NOTA, p- CH2CH2CH2NH2 - Bn-NOTA. This shows that -NH 2 in the chelating agent is in the meta position of the benzene ring. After the chelating agent m-NH 2 -Bn-NOTA binds heavy metal ions, it can better display the structure of heavy metal copper ions in terms of spatial structure. The results showed that the artificial antigen prepared by the meta structure also had the highest binding ratio. As an antigenic determinant, it was more conducive to the preparation of anti-heavy metal monoclonal antibodies with higher affinity, sensitivity and specificity.
实施例10Example 10
杂交瘤细胞株的筛选和单克隆抗体的制备纯化Screening of hybridoma cell lines and preparation and purification of monoclonal antibodies
(1)小鼠免疫:(1) Mice immunization:
选择6~8周龄、体重18~20g BALB/C雌性小鼠。将制备的免疫原(此处免疫原采用的是:铜离子人工抗原Cu-L2-BSA)与等体积弗氏完全佐剂采用注射器加压充分混合乳化后,通过腹部和腋下多点注射,剂量为50~100μg/只,后每间隔21d进行加强免疫,3次加强免疫后采血测定效价,效价采用间接ELISA方法测定,血清用封闭液倍比稀释后ELISA法测定抗血清效价,以免疫之前的小鼠血清为阴性对照,以阳性血清OD450nm值与阴性血清比值大于2.1所在稀释度为抗血清效价。当效价不再明显升高时进行末免,末免3d后进行细胞融合。免疫过程中第一次免疫使用弗氏完全佐剂,加强免疫采用弗氏不完全佐剂,末免不使用佐剂,直接免疫原注射免疫。BALB/C female mice aged 6-8 weeks and weighing 18-20 g were selected. The prepared immunogen (the immunogen used here is: copper ion artificial antigen Cu-L 2 -BSA) and an equal volume of Freund's complete adjuvant are fully mixed and emulsified by syringe pressure, and injected through the abdomen and axilla at multiple points. , the dose is 50-100 μg/a, and then booster immunization is carried out every 21d. After 3 booster immunizations, blood is collected to measure the titer, and the titer is measured by indirect ELISA method. , the mouse serum before immunization was used as the negative control, and the dilution at which the ratio of the positive serum OD 450nm value to the negative serum was greater than 2.1 was used as the antiserum titer. When the titer was no longer significantly increased, the final immunity was performed, and cell fusion was performed 3 days after the final immunity. In the immunization process, Freund's complete adjuvant was used for the first immunization, and Freund's incomplete adjuvant was used for booster immunization.
效价测定采用间接ELISA方法,具体实验步骤如下:The titer was determined by an indirect ELISA method, and the specific experimental steps were as follows:
a.包被:以Cu-L2-OVA为包被原,pH 9.6,0.05mol·L-1CBS为包被缓冲液,包被原浓度为10μg·mL-1,包被量为100μL/孔,37℃中包被2h后,PBST洗液洗板4次;a. Coating: Take Cu-L 2 -OVA as the coating source, pH 9.6, 0.05mol·L -1 CBS as the coating buffer, the coating concentration is 10μg·mL -1 , and the coating amount is 100μL/ Well, after coating for 2 hours at 37°C, the plate was washed 4 times with PBST wash solution;
b.封闭:加入封闭液250μL/孔,37℃孵育30min后,PBST洗板4次,每孔加PBST 300μL,后PBST洗液洗板4次;b. Blocking: add 250 μL/well of blocking solution, incubate at 37°C for 30 min, wash the plate 4 times with PBST, add 300 μL of PBST to each well, and then wash the plate 4 times with PBST washing solution;
c.加抗血清:将小鼠采血获得的抗血清10000r·min-1离心5min后,吸取10μL加入到2mL封闭液(起始稀释倍数为200倍),后采用封闭液倍比稀释11个梯度和1个阴性对照,100μL/孔,每个梯度4个重复,37℃孵育1h,后PBST洗液洗板4次;c. Add antiserum: After centrifuging the antiserum obtained by blood collection of mice at 10000r·min -1 for 5 minutes, pipette 10μL into 2mL of blocking solution (the initial dilution factor is 200 times), and then use the blocking solution to dilute 11 gradients. and 1 negative control, 100 μL/well, 4 replicates for each gradient, incubate at 37°C for 1 h, and wash the plate 4 times with PBST wash;
d.加酶标二抗:反应结束后洗板4次,HRP标记的羊抗鼠二抗10000倍稀释后加入酶标板,100μL/孔,37℃孵育1h,后PBST洗液洗板4次;d. Add enzyme-labeled secondary antibody: After the reaction, wash the plate 4 times. After the HRP-labeled goat anti-mouse secondary antibody is diluted 10,000 times, add it to the enzyme-labeled plate, 100 μL/well, incubate at 37 °C for 1 h, and then wash the plate 4 times with PBST washing solution. ;
e.加底物反应液:加入TMB底物缓冲液,100μL/孔,37℃孵育15min;e. Add substrate reaction solution: add TMB substrate buffer, 100μL/well, incubate at 37°C for 15min;
f.终止读数:加入2mol·L-1硫酸50μL/孔,用酶标仪读取OD450nm值。f. Stop reading: add 50 μL/well of 2 mol·L -1 sulfuric acid, and read the OD 450nm value with a microplate reader.
(2)细胞融合及培养:(2) Cell fusion and culture:
在末免3d后,按照常规聚乙二醇(PEG1500)方法进行细胞融合,具体步骤如下:After 3 days of final immunity, cell fusion was performed according to the conventional polyethylene glycol (PEG1500) method, and the specific steps were as follows:
a.末免后的小鼠眼球放血,血清收集后离心吸上清备用,拉颈处死后置于70%酒精中3~5min,无菌条件下取小鼠脾脏,用无菌手术剪剪碎后置入无菌碾钵中碾磨,用RPMI-1640基础培养基吹悬细胞后,过200目细胞筛网得到脾细胞悬液,并进行细胞计数;a. The eyeballs of the mice after the final immunization were bled, the serum was collected, and the supernatant was centrifuged for use. After being sacrificed by neck pulling, they were placed in 70% alcohol for 3-5 minutes. The spleen of the mice was taken under aseptic conditions and cut into pieces with sterile surgical scissors. Then put it into a sterile mortar for grinding, and suspend the cells with RPMI-1640 basal medium, then pass through a 200-mesh cell screen to obtain a spleen cell suspension, and count the cells;
b.收集SP2/0细胞(骨髓瘤细胞),要求细胞生长状态佳,细胞活性大于90%,吸去细胞上清后加入新的RPMI-1640基础培养基并将细胞吹打悬浮,后进行细胞计数;b. Collect SP2/0 cells (myeloma cells), the cell growth state is required to be good, and the cell viability is greater than 90%. After aspirating the cell supernatant, add a new RPMI-1640 basal medium and pipetting the cells to suspend, and then count the cells. ;
c.根据细胞计数结果,将脾细胞与SP2/0细胞按照5~10:1的比例混合后,1800r·min-1离心5min后吸去上清,剩余细胞加入0.5mL PEG在1min内边加边轻轻搅拌混匀,加完后静置1min后由慢到快加入RPMI-1640基础培养基45mL,后1500r·min-1离心5min后去上清,加入选择性HAT培养基后铺板于96孔细胞培养板,每孔250μL,置于37℃,5%CO2的培养箱中培养。c. According to the cell count results, mix splenocytes and SP2/0 cells in a ratio of 5-10:1, centrifuge at 1800 r·min -1 for 5 min, remove the supernatant, and add 0.5 mL of PEG to the remaining cells within 1 min. Gently stir and mix well. After adding, let stand for 1 min and then add 45 mL of RPMI-1640 basal medium from slow to fast. After centrifugation at 1500 r·min -1 for 5 min, remove the supernatant, add selective HAT medium and plate at 96 Well cell culture plates, 250 μL per well, were placed in an incubator at 37 °C, 5% CO 2 .
d.培养3~5d(天)后,用HAT培养基换液1次,第10d换为HT培养基培养。d. After culturing for 3 to 5 days (days), the medium was changed once with HAT medium, and the 10th day was changed to HT medium for culture.
(3)细胞筛选与细胞株建立:(3) Cell screening and establishment of cell lines:
待融合细胞生长到覆盖培养孔10%~30%孔底面积时,取上清用间接ELISA筛选抗体阳性孔,筛选时包被抗原为Cu-L2-OVA交联物,并以OVA、BSA作阴性对照。筛选出的阳性反应孔进一步用竞争ELISA分析抗体的检测灵敏度。When the fused cells grow to cover 10% to 30% of the bottom area of the culture well, take the supernatant and screen the antibody - positive wells by indirect ELISA. as a negative control. The selected positive reaction wells were further analyzed for the detection sensitivity of the antibody by competitive ELISA.
根据建立的标准曲线,计算IC50值和IC20值,选取标准曲线斜率范围(横坐标为铜离子标准品浓度的自然对数,纵坐标为抑制率建立的竞争标准曲线)在8~13之间,IC50值低于200ng·ml-1,IC20值低于20ng·ml-1的细胞株进行进一步的克隆和筛选,用有限稀释法连续克隆3~4次,最终获得一株杂交瘤细胞株6F9,其保藏编号为CGMCC No.16388。相对来说,IC20数值较低,IC50数值较低的细胞株的抑制效果较好,有利于制备特性较佳的杂交瘤细胞株。According to the established standard curve, calculate the IC 50 value and IC 20 value, and select the slope range of the standard curve (the abscissa is the natural logarithm of the copper ion standard concentration, and the ordinate is the competition standard curve established by the inhibition rate) between 8 and 13. In between, the cell lines with IC 50 value lower than 200ng·ml -1 and IC 20 value lower than 20ng·ml -1 were further cloned and screened, and cloned for 3 to 4 times by limiting dilution method, and finally a hybridoma was obtained. Cell line 6F9, its deposit number is CGMCC No.16388. Relatively speaking, a cell line with a lower IC 20 value and a lower IC 50 value has a better inhibitory effect, which is beneficial to the preparation of a hybridoma cell line with better characteristics.
该杂交瘤细胞株6F9已于2018年09月25日保藏于中国微生物菌种保藏管理委员会普通微生物中心(简称CGMCC,地址:中国科学院微生物研究所,北京市朝阳区北辰西路1号院3号,邮编100101)。The hybridoma cell line 6F9 has been deposited on September 25, 2018 in the General Microbiology Center of China Microorganism Culture Collection Management Committee (CGMCC for short, address: Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing , 100101).
最终获得的杂交瘤细胞株6F9经扩大培养后,一方面将该细胞株移入细胞冻存管并放入液氮中长期保存,另一方面将该细胞株用于腹水制备、单克隆抗体的纯化和应用。After the finally obtained hybridoma cell line 6F9 is expanded and cultured, on the one hand, the cell line is transferred into a cell cryopreservation tube and placed in liquid nitrogen for long-term storage, and on the other hand, the cell line is used for ascites preparation and monoclonal antibody purification. and application.
(3)单克隆抗体的制备、纯化和鉴定(3) Preparation, purification and identification of monoclonal antibodies
采用动物体内诱生法制备单克隆抗体。Monoclonal antibodies were prepared by in vivo induction in animals.
选择6~8周龄健康BALB/C雌性小鼠,在BALB/C小鼠腹腔注射降植烷0.3mL/只,7~10d后同法注射筛选到的6F9单克隆细胞株细胞(0.4mL/只,每ml细胞株数量在2.5×106~1×107之间),5~7d后待小鼠腹腔明显胀大后抽取腹水,离心除去油脂沉淀后,即得小鼠腹水McAb。Healthy BALB/C female mice aged 6-8 weeks were selected, BALB/C mice were injected intraperitoneally with 0.3 mL/mice of pristane, and 7-10 days later, the screened 6F9 monoclonal cells (0.4 mL/mice were injected in the same way). The number of cell lines per ml was between 2.5×10 6 and 1×10 7 ). After 5 to 7 days, the ascites was extracted after the abdominal cavity of the mice was obviously distended.
腹水采用辛酸-硫酸铵法初步纯化后,过亲合层析柱(填料为TOSOH公司生产的TOYOPEARL AF-rProtein A HC-650F)进一步纯化,用紫外分光光度计分别测定纯化单克隆抗体的紫外260nm和280nm的光密度,用Lowry-kalokar公式计算单克隆抗体浓度为2.43mg·mL-1,其余纯化的单克隆抗体-70℃保存备用。After the ascites was initially purified by the octanoic acid-ammonium sulfate method, it was further purified by an affinity chromatography column (the filler was TOYOPEARL AF-rProtein A HC-650F produced by TOSOH). and the optical density at 280 nm, the concentration of monoclonal antibody was calculated by Lowry-kalokar formula to be 2.43 mg·mL -1 , and the remaining purified monoclonal antibodies were stored at -70°C for future use.
腹水纯化具体步骤如下:The specific steps of ascites purification are as follows:
1)将腹水用60mmol·L-1pH 4.0的醋酸盐缓冲溶液按1:4体积比稀释,用0.1mol·L-1NaOH调节pH值至4.5;1) Dilute the ascites with 60 mmol·L -1 acetate buffer solution of pH 4.0 at a volume ratio of 1:4, and adjust the pH value to 4.5 with 0.1 mol · L -1 NaOH;
2)磁力搅拌下按照33μl·mL-1腹水的比例滴加辛酸,后室温下搅拌30min,于4℃静置2h,后10000r·min-1离心30min;2) Caprylic acid was added dropwise at a ratio of 33 μl·mL -1 ascites under magnetic stirring, followed by stirring at room temperature for 30 minutes, standing at 4°C for 2 hours, and then centrifuging at 10000 r·min -1 for 30 minutes;
3)上清用定性滤纸过滤后,按照1:10(PBS:过滤后的上清)比率加入0.1mol·L- 1PBS,用1mol·L-1NaOH调节pH至7.4,置于4℃30min;3) After the supernatant was filtered with qualitative filter paper, 0.1 mol·L -1 PBS was added at a ratio of 1:10 (PBS: filtered supernatant), the pH was adjusted to 7.4 with 1 mol·L -1 NaOH, and placed at 4°C for 30 min ;
4)在磁力搅拌下按照0.277g·mL-1(硫酸铵:混合液)比率分批加入硫酸铵,加完后搅拌反应30min,4℃静置3h,12000r·min-1离心30min,弃上清;4) Under magnetic stirring, ammonium sulfate was added in batches at a ratio of 0.277 g·mL -1 (ammonium sulfate: mixed solution), and after the addition, the reaction was stirred for 30 minutes, left standing at 4°C for 3 hours, centrifuged at 12000 r·min -1 for 30 minutes, and discarded. clear;
5)沉淀用少量0.01mol·L-1PBS溶解后置于透析袋中,用pH 7.4,0.01mol·L-1的PBS透析,中间换液4~6次;5) The precipitate is dissolved with a small amount of 0.01mol·L -1 PBS and placed in a dialysis bag, dialyzed with pH 7.4, 0.01mol·L -1 PBS, and the medium is exchanged 4 to 6 times;
6)初步纯化的单克隆抗体溶液过Protein A(TOYOPEARL AF-rProtein AHC-650F)亲合层析柱进行纯化,纯化后将抗体进行冷冻干燥后于-70℃保存备用。6) The preliminary purified monoclonal antibody solution was purified by protein A (TOYOPEARL AF-rProtein AHC-650F) affinity chromatography column. After purification, the antibody was freeze-dried and stored at -70°C for later use.
实施例11Example 11
单克隆抗体间接竞争ELISA方法的建立Establishment of an indirect competitive ELISA method for monoclonal antibodies
单克隆抗体工作浓度测定采用正交试验进行,具体实验步骤如下:The determination of the working concentration of monoclonal antibody is carried out by orthogonal test, and the specific experimental steps are as follows:
1)包被:以pH 9.6,0.05mol·L-1CBS为包被缓冲液,Cu-L2-OVA为包被原,包被量按照10μg·mL-1开始倍比稀释,包被体积为100μL/孔,37℃孵育2h后,PBST洗液洗板4次;1) Coating: take pH 9.6, 0.05mol·L -1 CBS as the coating buffer, Cu-L 2 -OVA as the coating source, the coating amount is diluted by 10 μg·mL -1 at the beginning, and the coating volume 100 μL/well, after incubation at 37°C for 2 h, the plate was washed 4 times with PBST wash solution;
2)封闭:加入封闭液250μL/孔,37℃孵育30min后,PBST洗液洗板4次;2) Blocking: Add 250 μL/well of blocking solution, incubate at 37°C for 30 min, and wash the plate 4 times with PBST washing solution;
3)加样:加入纯化后的单克隆抗体,按照10μg·mL-1开始倍比稀释后加入包被孔中,100μL/孔,37℃反应1h后,PBST洗液洗板4次;3) Sample loading: Add the purified monoclonal antibody, and then add it to the coated wells after initial doubling dilution of 10 μg·mL -1 , 100 μL/well, react at 37°C for 1 hour, and wash the plate 4 times with PBST washing solution;
4)加酶标二抗:反应结束后洗板4次,HRP标记的羊抗鼠二抗用封闭液10000倍稀释后加入酶标板,100μL/孔,37℃反应1h后,PBST洗液洗板4次;4) Add enzyme-labeled secondary antibody: after the reaction, wash the plate 4 times. HRP-labeled goat anti-mouse secondary antibody is diluted 10,000 times with blocking solution and then added to the enzyme-labeled plate, 100 μL/well, react at 37 °C for 1 h, and wash with PBST washing solution plate 4 times;
5)加底物反应液:加入TMB底物缓冲液,100μL/孔,37℃孵育15min;5) Add substrate reaction solution: add TMB substrate buffer, 100 μL/well, and incubate at 37°C for 15 min;
6)终止读数:加入2mol·L-1硫酸50μL/孔,酶标仪读取OD450nm值。6) Stop reading: add 50 μL/well of 2 mol·L -1 sulfuric acid, and read the OD 450nm value with a microplate reader.
7)选取OD450nm值在1.0-1.2区间的抗原抗体浓度组合为工作浓度,选取4个7) Select the antigen-antibody concentration combination with the OD 450nm value in the range of 1.0-1.2 as the working concentration, and select 4
工作浓度组合,其抗原、抗体的浓度组合分别为(0.625μg·mL-1,5μg·mL-1)、Working concentration combination, the concentration combination of antigen and antibody is (0.625μg·mL -1 , 5μg·mL -1 ),
(1.25μg·mL-1,2.μg·mL-1)、(2.5μg·mL-1,1.25μg·mL-1)和(5μg·mL-1,(1.25μg·mL -1 , 2.μg·mL -1 ), (2.5μg·mL -1 , 1.25μg·mL -1 ) and (5μg·mL -1 ,
0.625μg·mL-1),采用间接竞争ELISA法选定的4个工作浓度组合进行灵敏0.625μg·mL -1 ), using the combination of 4 working concentrations selected by the indirect competitive ELISA method for sensitive
度分析筛选,结果见表2,通过建立的标准曲线斜率、IC50值和标准曲线r值Degree analysis and screening, the results are shown in Table 2, through the established standard curve slope, IC 50 value and standard curve r value
等参数进行综合评价,确定最佳的工作浓度为抗原包被浓度1.25μg·mL-1,The optimal working concentration was determined to be the antigen coating concentration of 1.25μg·mL -1 , and other parameters were comprehensively evaluated.
抗体浓度为2.5μg·mL-1。The antibody concentration was 2.5 μg·mL -1 .
表2工作浓度分析结果Table 2 Working concentration analysis results
使用间接ELISA测定纯化单克隆抗体对铜离子螯合剂复合物的分析灵敏度IC20为0.14ng·mL-1,这说明制备得到的抗重金属铜离子单克隆抗体对铜离子有很高的检测灵敏度和很好的特异性,能够用于快速检测重金属铜离子。The analytical sensitivity IC 20 of the purified monoclonal antibody to the copper chelator complex by indirect ELISA was 0.14ng·mL -1 , which indicated that the prepared anti-heavy metal copper ion monoclonal antibody had high detection sensitivity and It has good specificity and can be used for rapid detection of heavy metal copper ions.
间接竞争ELISA具体步骤如下:The specific steps of indirect competition ELISA are as follows:
a.包被:以pH 9.6,0.05mol·L-1CBS为包被缓冲液,Cu-L2-OVA为包被原,包被体积为100μL/孔,包被浓度为前述筛选的最佳工作浓度,37℃孵育2h后,PBST洗液洗板4次;a. Coating: with pH 9.6, 0.05mol·L -1 CBS as coating buffer, Cu-L 2 -OVA as coating source, the coating volume is 100 μL/well, and the coating concentration is the best screened above Working concentration, after incubation at 37°C for 2h, the plate was washed 4 times with PBST wash solution;
b.封闭:加入封闭液250μL/孔,37℃孵育30min后,PBST洗液洗板4次;b. Blocking: Add 250 μL/well of blocking solution, incubate at 37°C for 30 min, and wash the plate 4 times with PBST washing solution;
c.样品前处理:5mmol·L-1 2-S-(2-氨基苯)-1,4,7三氮杂环壬烷-1,4,7-三乙酸即L1与不同浓度梯度重金属铜离子标样等体积混匀,37℃孵育1h;c. Sample pretreatment: 5mmol·L -1 2-S-(2-aminobenzene)-1,4,7 triazacyclononane-1,4,7-triacetic acid ie L 1 and heavy metals with different concentration gradients The copper ion standard sample was mixed in equal volume and incubated at 37°C for 1 h;
d.加样:加入预混好的样品50μL/孔,加入两倍最佳工作浓度一抗(即以上实施例10制备的抗铜离子单克隆抗体)50μL/孔,震荡混匀后37℃反应1h后,PBST洗液洗板4次;d. Add sample: add 50 μL/well of pre-mixed sample, add 50 μL/well of primary antibody twice the optimal working concentration (that is, the anti-copper ion monoclonal antibody prepared in Example 10 above), shake and mix well and react at 37°C After 1 h, the plate was washed 4 times with PBST washing solution;
e.加酶标二抗:反应结束后,洗板4次,HRP标记的羊抗鼠二抗用封闭液10000倍稀释后加入酶标板,100μL/孔,37℃反应1h后,PBST洗液洗板4次;e. Add enzyme-labeled secondary antibody: After the reaction, wash the plate 4 times, and add the HRP-labeled goat anti-mouse secondary antibody 10,000-fold with blocking solution and add it to the enzyme-labeled plate, 100 μL/well, react at 37°C for 1 h, wash with PBST Wash the plate 4 times;
f.加底物反应液:加入TMB底物缓冲液,100μL/孔,37℃孵育15min;f. Add substrate reaction solution: add TMB substrate buffer, 100μL/well, incubate at 37°C for 15min;
g.终止读数:加入2mol·L-1硫酸50μL/孔,酶标仪读取OD450nm值。g. Stop reading: add 50 μL/well of 2 mol·L -1 sulfuric acid, and read the OD 450nm value with a microplate reader.
溶液配制:Solution preparation:
碳酸盐缓冲液(CBS):称取Na2CO3 1.59g,NaHCO3 2.93g,加入纯水至990mL,调pH至9.6,再用纯水定容至1000mL,4℃贮存备用。Carbonate buffer solution (CBS): Weigh Na 2 CO 3 1.59 g, NaHCO 3 2.93 g, add pure water to 990 mL, adjust pH to 9.6, and then make up to 1000 mL with pure water, store at 4°C for later use.
磷酸缓冲液(PBS):8.5g NaCl,2.2g Na2HPO4·12H2O,0.2g NaH2PO4·2H2O,溶于900mL纯水中,调pH至7.4,定容至1000mL。Phosphate buffered saline (PBS): 8.5g NaCl, 2.2g Na 2 HPO 4 ·12H 2 O, 0.2g NaH 2 PO 4 ·2H 2 O, dissolved in 900 mL of pure water, adjusted to pH 7.4, and dilute to 1000 mL.
PBST洗液:取500mL 0.01mol·L-1PBS,加入0.25mL吐温20,混匀备用。PBST washing solution: take 500 mL of 0.01 mol·L -1 PBS, add 0.25 mL of Tween 20, and mix well for later use.
封闭液:1g脱脂奶粉溶解于50mL pH 7.4,0.01mol·L-1PBS。Blocking solution: 1 g of skim milk powder was dissolved in 50 mL of pH 7.4, 0.01 mol·L -1 PBS.
TMB底物缓冲液由A液,B液和C液组成,具体配方和使用体积比如下:TMB substrate buffer is composed of solution A, solution B and solution C. The specific formula and volume ratio are as follows:
显色液A:2.35g柠檬酸,9.2g Na2HPO4·12H2O,加纯水定容至490mL,调节pH值5.0~5.4,再用纯水定容至500mL,4℃贮存备用。Color developing solution A: 2.35g citric acid, 9.2g Na 2 HPO 4 ·12H 2 O, add pure water to make up to 490mL, adjust pH to 5.0-5.4, then make up to 500mL with pure water, store at 4°C for later use.
显色液B:取30%双氧水1.25mL,用纯水定容至50mL,4℃贮存备用。Color developing solution B: Take 1.25 mL of 30% hydrogen peroxide, dilute to 50 mL with pure water, and store at 4°C for later use.
显色液C:取200mg四甲基联苯胺(TMB)溶解于100ml无水乙醇中,溶解后4℃贮存备用。Color developing solution C: Dissolve 200 mg of tetramethylbenzidine (TMB) in 100 ml of absolute ethanol, and store at 4° C. for later use after dissolving.
TMB底物缓冲液使用前临时配用,配用比率为A液9.5mL,B液42μL,C液0.5mL,混匀后使用。The TMB substrate buffer is temporarily prepared before use, and the mixing ratio is 9.5 mL of A solution, 42 μL of B solution, and 0.5 mL of C solution, and used after mixing.
羊抗鼠HRP标记酶标二抗购自于Sigma公司。Goat anti-mouse HRP-labeled secondary antibody was purchased from Sigma Company.
实施例12Example 12
水样样品中添加回收率的实验Experiment of adding recovery rate in water sample
对实际样品进行添加回收实验,分别以自来水,湖泊水为实验对象,重金属铜离子的添加浓度分别为10ng·mL-1和50ng·mL-1,样品前处理步骤为:Addition and recovery experiments were carried out on the actual samples. Tap water and lake water were used as experimental objects. The concentration of heavy metal copper ions was 10ng·mL -1 and 50ng·mL -1 respectively. The sample pretreatment steps were as follows:
湖泊水样:湖泊水先用定性滤纸过滤后,添加铜离子标准溶液,自来水直接添加铜离子标准溶液,添加后铜离子最终浓度为10ng·mL-1和50ng·mL-1,添加混匀后,分别吸取100μL混匀后的自来水、湖泊水样品与5mmol·L-1L2等体积预混,后每孔加入50μL上述预混合后的自来水、湖泊水样品到反应孔中,3个重复孔,再加入50μL两倍最佳工作浓度的一抗(即以上实施例10制备的抗铜离子单克隆抗体),混匀后置于37℃孵育。后续实验步骤与上述实施例11中间接竞争ELISA反应步骤一致。自来水、湖泊水样品中添加回收率实验结果见表4。Lake water sample: The lake water is filtered with qualitative filter paper, then the copper ion standard solution is added , and the tap water is directly added with the copper ion standard solution. Pipette 100 μL of the mixed tap water and lake water samples and premix them with an equal volume of 5 mmol·L -1 L 2 respectively, and then add 50 μL of the above premixed tap water and lake water samples to each well. Then add 50 μL of primary antibody twice the optimal working concentration (ie, the anti-copper ion monoclonal antibody prepared in Example 10 above), mix well, and incubate at 37°C. Subsequent experimental steps are consistent with the indirect competition ELISA reaction steps in Example 11 above. Table 4 shows the experimental results of adding recovery rates to tap water and lake water samples.
表4水样样品添加回收率结果Table 4 Water sample addition recovery results
由添加回收率实验可以得出检测结果的准确度,以上的添加回收率值可以说明采用此方法测得的检测结果准确度较高,而且检测结果变异系数低,说明检测结果稳定性好。这说明制备得到的抗重金属铜离子单克隆抗体能够用于快速、准确地检测重金属铜离子。The accuracy of the detection results can be obtained from the addition recovery experiment. The above addition recovery values can indicate that the detection results measured by this method have high accuracy, and the coefficient of variation of the detection results is low, indicating that the detection results are stable. This shows that the prepared anti-heavy metal copper ion monoclonal antibody can be used for rapid and accurate detection of heavy metal copper ions.
上述实施例10-12中,将人工抗原Cu-L2-BSA替换为Cu-L1-BSA,包被原Cu-L2-OVA替换为Cu-L1-OVA,或者将人工抗原Cu-L2-BSA替换为Cu-L3-BSA,包被原Cu-L2-OVA替换为Cu-L3-OVA,或者将人工抗原Cu-L2-BSA替换为Cu-L4-BSA,包被原Cu-L2-OVA替换为Cu-L4-OVA,采用以上相同的制备方法可以制得不同的杂交瘤细胞株、抗重金属铜离子单克隆抗体以及使用间接竞争ELISA方法对铜离子进行检测。In the above Examples 10-12, the artificial antigen Cu-L 2 -BSA was replaced with Cu-L 1 -BSA, the original Cu-L 2 -OVA coated with Cu-L 1 -OVA was replaced, or the artificial antigen Cu- Replace L 2 -BSA with Cu-L 3 -BSA, replace the original Cu-L 2 -OVA with Cu-L 3 -OVA , or replace the artificial antigen Cu-L 2 -BSA with Cu-L 4 -BSA, Coating the original Cu-L 2 -OVA was replaced by Cu-L 4 -OVA, using the same preparation method above, different hybridoma cell lines, anti-heavy metal copper ion monoclonal antibodies, and indirect competition ELISA method can be used to prepare copper ions. test.
上述实施例1-12中,将其中的牛血清白蛋白BSA替换成钥孔血蓝蛋白KLH或者其他载体蛋白,采用以上相同的制备方法,也可以制备铜离子人工抗原、杂交瘤细胞株、单克隆抗体以及使用间接ELISA对铜离子进行检测。In the above-mentioned embodiment 1-12, the bovine serum albumin BSA is replaced with keyhole limpet hemocyanin KLH or other carrier proteins, and the same preparation method as above can also be used to prepare copper ion artificial antigens, hybridoma cell lines, single Antibodies were cloned and copper ions were detected using an indirect ELISA.
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811506878.7A CN110408600A (en) | 2018-12-10 | 2018-12-10 | A hybridoma cell line secreting anti-heavy metal copper ion monoclonal antibody and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811506878.7A CN110408600A (en) | 2018-12-10 | 2018-12-10 | A hybridoma cell line secreting anti-heavy metal copper ion monoclonal antibody and its application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110408600A true CN110408600A (en) | 2019-11-05 |
Family
ID=68357494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811506878.7A Pending CN110408600A (en) | 2018-12-10 | 2018-12-10 | A hybridoma cell line secreting anti-heavy metal copper ion monoclonal antibody and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110408600A (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993008837A1 (en) * | 1991-10-28 | 1993-05-13 | The Wellcome Foundation Limited | Stabilised antibodies |
| CN101560257A (en) * | 2009-04-27 | 2009-10-21 | 南京农业大学 | Heavy metal copper monoclonal antibody and preparation method thereof |
| CN101914153A (en) * | 2010-07-05 | 2010-12-15 | 吉林大学 | A kind of Pb2+ antigen and corresponding monoclonal antibody and preparation method thereof |
| CN101968481A (en) * | 2010-08-13 | 2011-02-09 | 中国农业大学 | Method for detecting existence of heavy metal copper ion in sample and special kit thereof |
| CN101979511A (en) * | 2010-11-05 | 2011-02-23 | 北京市农林科学院 | A monoclonal antibody against heavy metal zinc |
| CN102071170A (en) * | 2010-11-05 | 2011-05-25 | 北京市农林科学院 | Monoclonal antibody capable of resisting heavy metal copper and preparation method thereof |
| CN107955070A (en) * | 2017-12-07 | 2018-04-24 | 浙江工商大学 | The purposes of a kind of synthetic method and NOTA of improved artificial antigen of heavy metal copper in artificial antigen of heavy metal copper reagent is prepared |
-
2018
- 2018-12-10 CN CN201811506878.7A patent/CN110408600A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993008837A1 (en) * | 1991-10-28 | 1993-05-13 | The Wellcome Foundation Limited | Stabilised antibodies |
| CN101560257A (en) * | 2009-04-27 | 2009-10-21 | 南京农业大学 | Heavy metal copper monoclonal antibody and preparation method thereof |
| CN101914153A (en) * | 2010-07-05 | 2010-12-15 | 吉林大学 | A kind of Pb2+ antigen and corresponding monoclonal antibody and preparation method thereof |
| CN101968481A (en) * | 2010-08-13 | 2011-02-09 | 中国农业大学 | Method for detecting existence of heavy metal copper ion in sample and special kit thereof |
| CN101979511A (en) * | 2010-11-05 | 2011-02-23 | 北京市农林科学院 | A monoclonal antibody against heavy metal zinc |
| CN102071170A (en) * | 2010-11-05 | 2011-05-25 | 北京市农林科学院 | Monoclonal antibody capable of resisting heavy metal copper and preparation method thereof |
| CN107955070A (en) * | 2017-12-07 | 2018-04-24 | 浙江工商大学 | The purposes of a kind of synthetic method and NOTA of improved artificial antigen of heavy metal copper in artificial antigen of heavy metal copper reagent is prepared |
Non-Patent Citations (1)
| Title |
|---|
| FENGQUAN LIU 等: "Preparation and characterization of monoclonal antibody specific for copper-chelate complex", 《J IMMUNOL METHODS》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN116376847B (en) | A hybridoma cell line secreting monoclonal antibody against famoxadone and its application | |
| CN101486767A (en) | Mercury resistant chelate monoclonal antibody, as well as preparation method and application thereof | |
| Skvaril et al. | Distribution of IgA subclasses in sera and bone marrow plasma cells of 21 normal individuals | |
| CN101914153B (en) | A kind of Pb2+ antigen and corresponding monoclonal antibody and preparation method thereof | |
| CN106282126B (en) | A monoclonal antibody hybridoma cell line YH2 against heavy metal cadmium and its application | |
| CN112574956B (en) | Hybridoma cell strain secreting propamocarb monoclonal antibody and application thereof | |
| CN110879293A (en) | Method for screening hybridoma cell strain secreting pairing monoclonal antibody and application | |
| CN102876634B (en) | PMSG (pregnant mare serum gonadotropin) double-antibody sandwich ELISA (enzyme-linked immunosorbent assay) kit | |
| CN110407931A (en) | A kind of lead ion artificial antigen and its application | |
| CN110408599A (en) | A hybridoma cell line secreting anti-heavy metal lead ion monoclonal antibody and its application | |
| CN114058594B (en) | Hybridoma cell strain secreting vitamin A monoclonal antibody and application thereof | |
| CN104312978A (en) | Tobramycin monoclonal antibody as well as preparation method and application of tobramycin monoclonal antibody | |
| CN110407932A (en) | A kind of lead ion artificial antigen and its application | |
| CN110408598A (en) | A hybridoma cell line secreting anti-heavy metal lead ion monoclonal antibody and its application | |
| CN110408600A (en) | A hybridoma cell line secreting anti-heavy metal copper ion monoclonal antibody and its application | |
| CN110407930A (en) | A kind of copper ion artificial antigen and its application | |
| CN105087498A (en) | TCMTB monoclonal antibody hybridoma cell strain and application thereof | |
| CN110407928A (en) | A kind of cadmium ion artificial antigen and its application | |
| CN110408601A (en) | A hybridoma cell line secreting anti-heavy metal cadmium ion monoclonal antibody and its application | |
| CN110407929A (en) | A kind of cadmium ion artificial antigen and its application | |
| CN107955069A (en) | The purposes of a kind of synthetic method and DOTA of improved heavy metal lead artificial antigen in heavy metal lead artificial antigen reagent is prepared | |
| CN110408597A (en) | A hybridoma cell line secreting anti-heavy metal cadmium ion monoclonal antibody and its application | |
| CN104004718B (en) | One strain anti-Pirlimycin general purpose single monoclonal hybridomas cell line and application thereof | |
| CN102942519B (en) | Nitenpyram hapten, artificial antigen and antibody, and preparation method and application thereof | |
| CN118420487A (en) | Perfluoro caprylic hapten as well as preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191105 |